[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1315
1. Mendonça R, Lima LG, Fernandes LN, Ferreira NP, De Napoli G: [Primary connus medullaris glioblastoma: case report]. Arq Neuropsiquiatr; 2005 Jun;63(2B):539-42
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary connus medullaris glioblastoma: case report].
  • [Transliterated title] Glioblastoma primário de cone medula: relato de caso.
  • Glioblastomas are the most common type of brain tumors; astrocytic in their origin, they are anaplastic tumors, and are located mainly in the cerebral hemispheres.
  • We present here the case of a 39 years-old man with an intramedullary tumor of the spinal cord, with an histo pathological diagnosis of glioblastoma, along with some therapeutic considerations.
  • [MeSH-major] Glioblastoma / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059615.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Chaddad Neto F, Lopes A, Alberto Filho M, Catanoce A, Joaquim AF, Oliveira Ed: Tectal glioblastoma. Arq Neuropsiquiatr; 2007 Dec;65(4A):996-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tectal glioblastoma.
  • Brain stem gliomas are a heterogeneous group of neoplasms arising mostly in paediatric patients.
  • Tectal plate gliomas represent a particular type of brain stem tumours usually with a benign, indolent clinical course, presenting with signs of raised intracranial hypertension due to supra-tentorialhydrocephalous caused by aqueductal stenosis.
  • We present the case of a glioblastoma of the tectal plate in a 22 years-old woman operated upon by a supracerebellar-infratentorial approach.
  • [MeSH-major] Brain Neoplasms. Glioblastoma. Tectum Mesencephali
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094862.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Chong PK, Loo AV: Visual epilepsy in glioblastoma multiforme. Med J Malaysia; 2008 Dec;63(5):406-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual epilepsy in glioblastoma multiforme.
  • We report a 33-year-old Chinese gentleman who presented with visual epilepsy and symptoms of raised intracranial pressure in which clinical examination revealed normal visual fields and acuity despite Magnetic Resonance Imaging (MRI) brain showing large contrast enhancing mass at the right occipital lobe.
  • Craniotomy and excision of tumour was done and the histology confirmed glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / pathology. Epilepsies, Partial / pathology. Glioblastoma / pathology. Hallucinations / pathology. Occipital Lobe / pathology
  • [MeSH-minor] Adult. Cranial Irradiation. Craniotomy. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19803301.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


Advertisement
4. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC: Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med; 2010 May 12;2(31):31ra34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic modulation of glioblastoma with dichloroacetate.
  • Solid tumors, including the aggressive primary brain cancer glioblastoma multiforme, develop resistance to cell death, in part as a result of a switch from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis.
  • We tested whether the small-molecule and orphan drug dichloroacetate (DCA) can reverse this cancer-specific metabolic and mitochondrial remodeling in glioblastoma.
  • In a separate experiment with five patients who had glioblastoma, we prospectively secured baseline and serial tumor tissue, developed patient-specific cell lines of glioblastoma and putative glioblastoma stem cells (CD133(+), nestin(+) cells), and treated each patient with oral DCA for up to 15 months.
  • Metabolic modulation may be a viable therapeutic approach in the treatment of glioblastoma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / metabolism. Dichloroacetic Acid / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / metabolism
  • [MeSH-minor] Adult. Apoptosis / drug effects. Cell Line, Tumor. Female. Humans. In Vitro Techniques. Male. Membrane Potential, Mitochondrial / drug effects. Middle Aged. Mitochondria / drug effects. Mitochondria / metabolism. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / pathology. Neovascularization, Pathologic / drug therapy. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DICHLOROACETIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20463368.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 9LSH52S3LQ / Dichloroacetic Acid; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.2 / pyruvate dehydrogenase (acetyl-transferring) kinase
  •  go-up   go-down


5. Biswas T, Okunieff P, Schell MC, Smudzin T, Pilcher WH, Bakos RS, Vates GE, Walter KA, Wensel A, Korones DN, Milano MT: Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol; 2009;4:11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for glioblastoma: retrospective analysis.
  • PURPOSE: This retrospective study was done to better understand the conditions for which stereotactic radiosurgery (SRS) for glioblastoma may be efficacious.
  • METHODS: Between 2000 and 2007, 33 patients with a pathological diagnosis of glioblastoma received SRS with the Novalis Shaped Beam Radiosurgery system.
  • Eighteen patients (54%) underwent salvage SRS for recurrence while 15 (45%) patients received upfront SRS following standard fractionated RT for newly diagnosed glioblastoma.
  • CONCLUSION: SRS is well tolerated in the treatment of glioblastoma.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Salvage Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1991 Oct;75(4):559-63 [1653309.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207 [8380567.001]
  • [Cites] Radiother Oncol. 1994 Feb;30(2):146-9 [8184112.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):931-41 [7607967.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5 [9316038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):79-88 [9989517.001]
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):516-21 [15596923.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):318-27 [15890570.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55 [16111571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9 [16168843.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):210-7 [16175848.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2168-73 [16220556.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):348-64 [16713103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1422-8 [16750317.001]
  • [Cites] Brain. 2007 Oct;130(Pt 10):2596-606 [17785346.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1350-60 [18037587.001]
  • [Cites] J Neurooncol. 2008 Sep;89(3):313-37 [18712283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8 [10802351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1351-8 [11121633.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7 [11163499.001]
  • [Cites] Neurosurgery. 2002 Jan;50(1):41-6; discussion 46-7 [11844233.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1397-404 [12459362.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60 [15465203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1733-40 [231023.001]
  • [Cites] NCI Monogr. 1988;(6):279-84 [3281031.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1389-96 [2542193.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):769-74 [1654987.001]
  • (PMID = 19292912.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2662864
  •  go-up   go-down


6. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G, Workman P: Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther; 2010 May;9(5):1219-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
  • The dismal prognosis of glioblastoma (GB) indicates the urgent need for new therapies for these tumors.
  • Here, we explored the mechanistic potential of the potent synthetic diarylisoxazole amide resorcinol HSP90 inhibitor, NVP-AUY922, in adult and pediatric GB.
  • In vitro antiproliferative potency (nanomolar range) was seen in both adult and pediatric human GB cell lines with different molecular pathologies.
  • A cytostatic effect was observed in all GB lines; more apoptosis was observed at lower concentrations in the SF188 pediatric GB line and at 144 hours in the slower growing KNS42 pediatric GB line, as compared with the adult GB lines U87MG and SF268.
  • Our results have established a mechanistic proof of concept for the potential of novel synthetic HSP90 inhibitors in adult and pediatric GB, alone or in combination with phosphoinositide 3-kinase/mammalian target of rapamycin and mitogen-activated protein/ERK kinase inhibitors.
  • [MeSH-major] Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Isoxazoles / pharmacology. Isoxazoles / therapeutic use. Resorcinols / pharmacology. Resorcinols / therapeutic use
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Child. Dose-Response Relationship, Drug. Female. Humans. Maximum Tolerated Dose. Mice. Mice, Nude. Treatment Outcome. Xenograft Model Antitumor Assays


7. Jimenez Caballero PE, Mollejo Villanueva M, Marsal Alonso C: [Gliomatosis cerebri: evolution to glioblastoma multiforme]. Neurologia; 2007 Jul-Aug;22(6):395-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri: evolution to glioblastoma multiforme].
  • [Transliterated title] Gliomatosis cerebri: evolución a glioblastoma multiforme.
  • The brain magnetic resonance imaging showed hyperintense lesions in T2 suggestive of gliomatosis cerebri, this being confirmed with the brain biopsy.
  • Several months later, he suffered rapid clinical deterioration, observing the development of a glioblastoma multiforme over the lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610168.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 25
  •  go-up   go-down


8. Tramacere F, Gianicolo E, Serinelli M, Bambace S, De Luca M, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Distante A, Portaluri M: [Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"]. Clin Ter; 2008 Jul-Aug;159(4):233-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"].
  • [Transliterated title] Multivariate analysis of prognostic factors and survival inpatients with "glioblastoma multiforme".
  • PURPOSE: The aim of this study was to evaluate the survival of patients with "glioblastoma multiforme", to analyse the prognostic factors influencing the survival rate and to review recent results in the literature.
  • Among the factors under investigation we ascertained that sex, chemotherapy, conformal treatment, surgery, and the choice of the irradiation area (whole brain or only the involved field) did not influence the survival in a statistically significant manner.
  • [MeSH-major] Brain Neoplasms / mortality. Glioblastoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776979.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


9. Hernández-Reyna R, Medellín-Sánchez R, Cerda-Flores RM, Calderón-Garcidueñas AL: [Survival pronostic factors in Mexican patients with multiforme glioblastoma]. Rev Med Inst Mex Seguro Soc; 2010 Mar-Apr;48(2):121-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival pronostic factors in Mexican patients with multiforme glioblastoma].
  • [Transliterated title] Factores pronósticos de supervivencia en pacientes mexicanos con glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioblastoma / mortality. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cross-Sectional Studies. Female. Humans. Male. Mexico. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20929613.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


10. Baldi I, Huchet A, Bauchet L, Loiseau H: [Epidemiology of glioblastoma]. Neurochirurgie; 2010 Dec;56(6):433-40
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of glioblastoma].
  • An increasing incidence of glioblastoma has been observed over the last 30 years.
  • Moreover, the aging of the population and the increasing occurrence of glioblastoma beyond 60 years of age are additional explanations.
  • In Gironde (France), where a specialized registry has been established, the annual incidence of glioblastoma is 4.96/100,000.
  • Ethnicity, age, sex, hereditary syndromes, some constitutive polymorphisms, and brain irradiation are the established risk factors Allergies or asthma, certain viral infections, autoimmune diseases, nonsteroidal anti-inflammatory drug intake, substitutive hormonal therapy, and dietary antioxidant intake are the established protective factors.
  • Future studies combining constitutive polymorphisms and exposure assessment are likely to provide consistent and important data that will improve our knowledge in the epidemiology of glioblastoma.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20869733.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Seif FE, Azar S, Barake M, Sawaya R: Hypercalcemia in glioblastoma multiforme. Neuro Endocrinol Lett; 2006 Aug;27(4):547-8
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcemia in glioblastoma multiforme.
  • We report a case of a previously healthy man presenting with glioblastoma multiforme .
  • This is the first reported case of hypercalcemia associated with glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Hypercalcemia / etiology
  • [MeSH-minor] Adult. Calcitriol / blood. Calcium / blood. Humans. Male. Parathyroid Glands / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892004.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


12. Ances BM, Danish SF, Kolson DL, Judy KD, Liebeskind DS: Cerebral gumma mimicking glioblastoma multiforme. Neurocrit Care; 2005;2(3):300-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral gumma mimicking glioblastoma multiforme.
  • This article reports an unusual case of a syphilitic gumma with a clinical and radiographical presentation initially suggestive of glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / pathology. Glioblastoma / diagnostic imaging. Glioblastoma / pathology. Neurosyphilis / diagnostic imaging. Neurosyphilis / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Radiography

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2001 Feb;22(2):314-6 [11156776.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Jul;35(7):462-6 [7477692.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4):703-11 [7611026.001]
  • (PMID = 16159080.001).
  • [ISSN] 1541-6933
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kartashev AV, Vinogradov VM: [Postoperative chemoradiotherapy for cerebral glioblastoma]. Vopr Onkol; 2008;54(4):471-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative chemoradiotherapy for cerebral glioblastoma].
  • We developed a new method of accelerated chemoimmunoradiotherapy for cerebral glioblastoma and evaluated the immediate effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Immunotherapy / methods. Interleukin-2 / therapeutic use
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Dose Fractionation. Drug Administration Schedule. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Postoperative Period. Radiotherapy, Adjuvant. Recombinant Proteins / therapeutic use. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942402.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; U68WG3173Y / Carmustine
  •  go-up   go-down


14. Umesh S, Tandon A, Santosh V, Anandh B, Sampath S, Chandramouli BA, Sastry Kolluri VR: Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin Neuropathol; 2009 Sep-Oct;28(5):362-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
  • OBJECTIVE: Glioblastomas are the commonest and the most malignant of all adult brain tumors, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior.
  • MATERIALS AND METHODS: We evaluated 54 cases of adult supratentorial glioblastomas operated over a span of 1 year, with respect to clinical features such as age, Karnofsky performance score (KPS), extent of resection, adjuvant therapy, and immunohistochemical expression of p53, EGFR (Epidermal Growth Factor Receptor) and PTEN (Phosphatase and Tensin homolog).
  • CONCLUSIONS: Our study shows that EGFR and p53 overexpression along with loss of PTEN expression are important adjuncts to clinical variables in prognosticating glioblastoma patients.
  • [MeSH-major] Glioblastoma / diagnosis. Supratentorial Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. PTEN Phosphohydrolase / metabolism. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Severity of Illness Index. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788052.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


15. Pistollato F, Abbadi S, Rampazzo E, Viola G, Della Puppa A, Cavallini L, Panchision DM, Te Kronnie G, Basso G: Glioblastoma-derived cells exhibit differential responses to glycolysis inhibition under hypoxia. J Clin Oncol; 2009 May 20;27(15_suppl):e13031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma-derived cells exhibit differential responses to glycolysis inhibition under hypoxia.
  • : e13031 It has been suggested that oxygen tension is a crucial component of the brain tumor niche, as hypoxia positively correlates with tumor aggressiveness and over-activity of hypoxia inducible factor-1α (HIF-1α) reinforces tumor progression.
  • Here we investigate the effects mediated by in vitro glycolysis inhibition by using 2-deoxyglucose (2-DG) in glioblastoma (GBM) derived cells maintained under two different oxygen tensions, a lowered oxygen tension (2%) versus a higher non-physiological (20%).
  • Our results show that adult GBM displaying a highly immature phenotype manifested the highest resistance to glucose deprivation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Stark AM, Maslehaty H, Hugo HH, Mahvash M, Mehdorn HM: Glioblastoma of the cerebellum and brainstem. J Clin Neurosci; 2010 Oct;17(10):1248-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma of the cerebellum and brainstem.
  • Glioblastoma multiforme (GB) is the most common and most malignant primary intracranial tumor.
  • Because of its rarity and the non-specific radiological features of iGB, it can easily be misdiagnosed as a brain metastasis, ependymoma or even as a benign lesion such as vestibular schwannoma or meningioma.
  • Postoperative adjuvant therapy similar to that for supratentorial glioblastoma is indicated.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Stem / pathology. Cerebellum / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20619657.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


17. Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U: Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology; 2009;76(3):184-9
Hazardous Substances Data Bank. TENIPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.
  • BACKGROUND: In a previous trial (NOA-01), the combination of nimustine and teniposide showed efficacy in previously untreated glioblastoma (GBM).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Nimustine / administration & dosage. Teniposide / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19218824.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0S726V972K / Nimustine; 957E6438QA / Teniposide
  •  go-up   go-down


18. Keir ST, Farland MM, Lipp ES, Friedman HS: Distress persists in long-term brain tumor survivors with glioblastoma multiforme. J Cancer Surviv; 2008 Dec;2(4):269-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distress persists in long-term brain tumor survivors with glioblastoma multiforme.
  • INTRODUCTION: Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor.
  • RESULTS: Eight-three brain tumor patients participated in this study.
  • CONCLUSIONS: This study indicates that LTS of GBM report experiencing distress at similar levels to other brain tumor patients.
  • [MeSH-major] Anxiety Disorders / epidemiology. Brain Neoplasms / psychology. Glioblastoma / psychology. Survivors
  • [MeSH-minor] Adult. Aged. Fatigue / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prevalence. Research Design


19. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma Network: Long-term survival with glioblastoma multiforme. Brain; 2007 Oct;130(Pt 10):2596-606
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with glioblastoma multiforme.
  • The median survival of glioblastoma patients is approximately 12 months.
  • To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular analysis of 55 primary glioblastoma long-term survivors recruited at the six clinical centres of the German Glioma Network and one associated centre.
  • Comparison of these data with results from an independent series of 141 consecutive unselected glioblastoma patients registered in the German Glioma Network revealed significantly more frequent MGMT hypermethylation in the long-term survivor group.
  • Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. DNA, Neoplasm / genetics. Female. Genes, erbB-1. Humans. Karnofsky Performance Status. Loss of Heterozygosity. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Prognosis. Risk Factors. Survivors. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785346.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 105
  •  go-up   go-down


20. Hassler M, Seidl S, Fazeny-Doerner B, Preusser M, Hainfellner J, Rössler K, Prayer D, Marosi C: Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet; 2006 Apr 1;166(1):46-55
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity of cytogenetic and pathohistologic profiles in glioblastoma.
  • We present a small series of patients with primary glioblastoma multiforme (GBM), and combine individual genetic data with pathohistologic characteristics and clinical outcome.
  • By classical banding methods, 15/18 patients showed at least one aberration characteristic for primary glioblastoma (+7 in 7/18, deletions of 9p in 10/18 and -10 or deletions from 10q in 8/18 patients).
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Variation. Glioblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Cycle Proteins / genetics. Chromosome Aberrations. DNA Methylation. Epigenesis, Genetic. Female. Fibroblast Growth Factor 2 / genetics. Gene Silencing. Homeodomain Proteins / genetics. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Neovascularization, Pathologic. O(6)-Methylguanine-DNA Methyltransferase / genetics. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Prognosis. Promoter Regions, Genetic. Survival Rate. Tumor Suppressor Proteins / genetics. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616111.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


21. Mou KJ, Mao Q, Chen MN, Xia XQ, Ni RY, Wang P, Liu YH: [AQP4 expression in the brains of patients with glioblastoma and its association with brain edema]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;40(4):651-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AQP4 expression in the brains of patients with glioblastoma and its association with brain edema].
  • OBJECTIVE: To investigate the expression of aquaporin-4 (AQP4) in the brains of patients with glioblastoma and its association with brain edema.
  • METHODS: Immunofluorescence cytochemistry and western blot tests were performed to detect the expression of AQP4 in the brain tumors and the adjacent tissues in 30 patients with glioblastoma.
  • The association between AQP4 and the extent of brain edema was analysed.
  • Higher expressions of AQP4 were found in the brain tumors and adjacent tissues in the patients with glioblastoma than in the normal controls (P<0.05).
  • The AQP4 was positively correlated with the extent of brain edema.
  • CONCLUSION: AQP4 overexpress in the brain tumors and adjacent tissues, which is associated with the extent of brain edema.
  • Cytotoxic and vasogenic edemas may coexist in the cerebral edema induced by glioblastoma.
  • [MeSH-major] Aquaporin 4 / metabolism. Brain Edema / etiology. Brain Neoplasms / metabolism. Glioblastoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764565.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Aquaporin 4
  •  go-up   go-down


22. Koul D: PTEN signaling pathways in glioblastoma. Cancer Biol Ther; 2008 Sep;7(9):1321-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN signaling pathways in glioblastoma.
  • Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy.
  • Deregulation of phosphatidylinositol 3-kinase (PI3K) signaling pathways resulting from genetic alterations in the PTEN tumor suppressor gene on 10q23 at the level of LOH, mutation and methylation have been identified in at least 60% of glioblastoma.
  • Loss of PTEN function by mutation or LOH correlates with poor survival in anaplastic astrocytoma and glioblastoma, suggesting that PTEN plays a role in patient outcome.
  • Interestingly, amplification of Epidermal growth factor receptor (EGFR) in the background of heterozygous PTEN knockout mice develop invasive glioma very similar to human glioblastoma, demonstrating the importance of PTEN in glioma progression and providing a model system to evaluate the efficacy of targeting PTEN in glioblastoma.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. PTEN Phosphohydrolase / genetics. Signal Transduction / physiology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adult. Humans


23. Bähr O, Herrlinger U, Weller M, Steinbach JP: Very late relapses in glioblastoma long-term survivors. J Neurol; 2009 Oct;256(10):1756-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late relapses in glioblastoma long-term survivors.
  • Long-term survival of patients with histologically confirmed glioblastoma is a rare event with figures in the range of 2-3% for 5-year survival (Scott et al. in Ann Neurol 46:183-188, 1999; McLendon and Halperin in Cancer 98:1745-1748, 2003; Krex et al. in Brain 130:2596-2606, 2007).
  • We here report on the extended follow-up (mean, 139.4 months) of a cohort of glioblastoma long-term survivors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survivors. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2007 Oct;130(Pt 10):2596-606 [17785346.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):61-4 [9525826.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]
  • (PMID = 19434438.001).
  • [ISSN] 1432-1459
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


24. Amini A, Schmidt RH, Salzman KL, Chin SS, Couldwell WT: Glioblastoma multiforme of the pineal region. J Neurooncol; 2006 Sep;79(3):307-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the pineal region.
  • Glioblastoma multiforme (GBMs) tumors are exceedingly rare tumors in the pineal region.
  • Glioblastoma should be considered in the differential diagnosis of the pineal region tumors, especially when evidence of leptomeningeal or ependymal metastatic disease is present.
  • [MeSH-major] Brain / pathology. Glioblastoma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / etiology. Tomography, X-Ray Computed. Vision Disorders / etiology. Vomiting / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] Arch Neurol. 1979 Nov;36(11):717-8 [508133.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Childs Nerv Syst. 1993 Nov;9(7):422-4 [8306360.001]
  • [Cites] Radiology. 1972 May;103(2):399-406 [4537183.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):275-80 [3883555.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):592-6 [6261912.001]
  • [Cites] Pediatr Neurosurg. 2003 Jun;38(6):307-23 [12759510.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):221-36 [15527093.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2B):468-72 [12894287.001]
  • [Cites] J Clin Neurosci. 2005 Sep;12(7):834-7 [16198924.001]
  • [Cites] J Neurosurg. 1973 Oct;39(4):455-62 [4730334.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] J Neurosurg Sci. 1990 Apr-Jun;34(2):149-50 [1965444.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 16645719.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hashiguchi A, Morioka M, Ichimura H, Mimata C, Kuratsu J: Glioblastoma with an intratumoral feeding-artery aneurysm. Clin Neurol Neurosurg; 2007 Apr;109(3):302-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma with an intratumoral feeding-artery aneurysm.
  • We report a patient with recurrent glioblastoma, in whom serial magnetic resonance angiography (MRA) demonstrated gradual enlargement of an artery feeding the tumor and the development of an intratumoral aneurysm that led to intratumoral hemorrhage.
  • This is a rare case of glioblastoma in which the association of an intratumoral feeding-artery aneurysm, whose rupture led to intratumoral bleeding, was documented by serial MRA imaging and follow-up.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Arteries / pathology. Cerebral Arteries / radiography. Glioblastoma / blood supply. Glioblastoma / diagnosis. Intracranial Aneurysm / pathology. Intracranial Aneurysm / radiography
  • [MeSH-minor] Adult. Aneurysm, Ruptured / radiography. Aneurysm, Ruptured / surgery. Female. Frontal Lobe / blood supply. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222964.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Kroonen J, Nguyen-Khac MT, Deprez M, Rogister B, Robe P: [Glioblastoma, an example of translational research?]. Rev Med Liege; 2008 May-Jun;63(5-6):251-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glioblastoma, an example of translational research?].
  • Among patients which develop glioblastoma multiform (GBM), recurrence is the rule despite continuous progress in surgery, radiotherapy and chemotherapy.
  • In the adult, GBM is the most frequent and most aggressive tumour of the Central Nervous System.
  • It is thus very attractive to speculate on a possible relationship between these GBM stem cells and the neural stem cells which are persisting in the neurogenic zones of the adult brain.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669189.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Belgium
  • [Number-of-references] 27
  •  go-up   go-down


27. Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rössler K, Budka H, Hainfellner JA: No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol; 2005 May;109(5):534-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No prognostic impact of survivin expression in glioblastoma.
  • In the present study we investigated the immunohistochemical expression of survivin and its prognostic impact in a large glioblastoma series comprising 104 consecutive adult patients undergoing a first operation for glioblastoma.
  • Survivin was expressed in all glioblastoma samples, and was prominent in a fraction of nuclei of tumor cells and vascular cells.
  • In summary, in glioblastoma, survivin is expressed predominantly in proliferating tumor cell nuclei.
  • [MeSH-major] Apoptosis / physiology. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western / methods. Cell Nucleus / metabolism. DNA Topoisomerases, Type II / metabolism. Female. Fluorescent Antibody Technique / methods. Humans. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / metabolism. Male. Microscopy, Confocal. Middle Aged. Models, Biological. Prognosis. Retrospective Studies. Statistics as Topic

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843906.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


28. Birbilis TA, Matis GK, Eleftheriadis SG, Theodoropoulou EN, Sivridis E: Spinal metastasis of glioblastoma multiforme: an uncommon suspect? Spine (Phila Pa 1976); 2010 Apr 1;35(7):E264-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal metastasis of glioblastoma multiforme: an uncommon suspect?
  • OBJECTIVE: To report a case and review the literature on glioblastoma multiforme (GBM) with drop-like metastasis to the spine.
  • SUMMARY OF BACKGROUND DATA: GBM constitutes the most common adult malignant brain tumor with poor prognosis.
  • CONCLUSION: Spinal metastases should be commonly suspected in patients with a history of intracranial GBM who complain about symptoms not explained by the primary lesion.Glioblastoma multiforme (GBM) was first described by Rudolph Virchow in 1863 and represents the most common and most malignant tumor of the cerebral hemispheres, usually arising between the ages of 40 and 60 years.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Pineal Gland / pathology. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195200.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shibahara J, Fukayama M: Secondary glioblastoma with advanced neuronal immunophenotype. Virchows Arch; 2005 Sep;447(3):665-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary glioblastoma with advanced neuronal immunophenotype.
  • We describe an unusual progression of astrocytoma into secondary glioblastoma exhibiting advanced neuronal immunophenotype.
  • Although the secondary tumor was classified as glioblastoma according to World Health Organization (WHO) classification (2000), it might be categorized into new variants of malignant glioneuronal tumors proposed recently.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Fatal Outcome. Humans. Immunohistochemistry. Immunophenotyping. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2004 Dec;55(6):1377-91: discussion 1391-2 [15574220.001]
  • [Cites] Clin Neuropathol. 1994 Jan-Feb;13(1):1-11 [7518371.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Am J Pathol. 1991 Jul;139(1):67-79 [1713022.001]
  • (PMID = 15968544.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


30. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M: Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials; 2010 Jan;5(1):14-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic paradigms in glioblastoma.
  • Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal adult primary brain tumor.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Clinical Trials as Topic. DNA Modification Methylases / analysis. DNA Repair Enzymes / analysis. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Humans. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Radiotherapy, Adjuvant. Receptor, Epidermal Growth Factor / antagonists & inhibitors. TOR Serine-Threonine Kinases. Tumor Suppressor Proteins / analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205684.001).
  • [ISSN] 1876-1038
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1RC2CA148190-01; United States / NCI NIH HHS / CA / 7R01CA108633-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 117
  •  go-up   go-down


31. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doğan AK, Akyüz F: Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON; 2006 Jan-Mar;11(1):39-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative hypofractionated radiotherapy in glioblastoma multiforme.
  • PURPOSE: To evaluate the safety and efficacy of hypofractionated radiotherapy (HRT) in glioblastoma multiforme (GM) patients in terms of overall and progression-free survival.
  • PATIENTS AND METHODS: Adult patients with GM were prospectively treated with HRT after total, subtotal or partial tumor excision.
  • Acute toxicity was minimal and only one HRT patient had late toxicity (brain necrosis).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Pilot Projects. Postoperative Period. Prognosis. Prospective Studies. Radiotherapy Planning, Computer-Assisted. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318950.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M: PCV chemotherapy for recurrent glioblastoma. Neurology; 2006 Feb 28;66(4):587-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCV chemotherapy for recurrent glioblastoma.
  • The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Recurrence. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505319.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


33. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol; 2007 Oct 20;25(30):4722-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
  • PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months.
  • After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab.
  • CONCLUSION: Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Apr;5(4):186-7 [18285760.001]
  • [CommentIn] J Clin Oncol. 2007 Oct 20;25(30):4705-6 [17947716.001]
  • [CommentIn] J Clin Oncol. 2008 Nov 10;26(32):5304-5; author reply 5305 [18854564.001]
  • [CommentIn] Nat Clin Pract Neurol. 2008 May;4(5):242-3 [18212790.001]
  • [CommentIn] J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013 [18281677.001]
  • (PMID = 17947719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 4 R37 CA11898; United States / NCI NIH HHS / CA / 5 P50 CA108786; United States / NINDS NIH HHS / NS / 5 P50 NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


34. Pistollato F, Abbadi S, Rampazzo E, Viola G, Della Puppa A, Cavallini L, Frasson C, Persano L, Panchision DM, Basso G: Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma. Biochem Pharmacol; 2010 Nov 15;80(10):1517-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma.
  • Glioblastoma multiforme (GBM) are highly proliferative brain tumors characterized by a hypoxic microenvironment which controls GBM stem cell maintenance.
  • [MeSH-major] Brain. Deoxyglucose / pharmacology. Glioblastoma. Succinic Acid / metabolism
  • [MeSH-minor] Adult. Apoptosis / drug effects. Blotting, Western. Cell Adhesion / drug effects. Cell Culture Techniques. Cell Differentiation / drug effects. Cell Hypoxia / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Cells, Cultured. Child. Glutathione / metabolism. Glycolysis. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Membrane Potential, Mitochondrial / drug effects. Oxygen / pharmacology. Reactive Oxygen Species / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Succinate Dehydrogenase / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SUCCINIC ACID .
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20705058.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Reactive Oxygen Species; 9G2MP84A8W / Deoxyglucose; AB6MNQ6J6L / Succinic Acid; EC 1.3.99.1 / Succinate Dehydrogenase; GAN16C9B8O / Glutathione; S88TT14065 / Oxygen
  •  go-up   go-down


35. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE: Neurological outcome of long-term glioblastoma survivors. J Neurooncol; 2009 Dec;95(3):301-305
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological outcome of long-term glioblastoma survivors.
  • Extended survival of 3 or more years is rare in patients with glioblastoma (GBM) but is becoming more common.
  • [MeSH-major] Brain Neoplasms / mortality. Cognition Disorders / mortality. Glioblastoma / mortality. Quality of Life. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Databases, Factual. Follow-Up Studies. Humans. Karnofsky Performance Status. Middle Aged. Neoplasm Recurrence, Local / mortality. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]
  • [Cites] Brain. 2007 Oct;130(Pt 10):2596-606 [17785346.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] J Neurol. 2009 Oct;256(10):1756-8 [19434438.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):201-6 [2821446.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Can J Neurol Sci. 1998 Aug;25(3):197-201 [9706720.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):506-9 [3418382.001]
  • [Cites] Clin Neurol Neurosurg. 1985;87(3):167-71 [2996816.001]
  • [Cites] J Neurooncol. 1996 Mar;27(3):259-66 [8847560.001]
  • [Cites] Neurosurgery. 1993 May;32(5):716-20; discussion 720 [8388081.001]
  • [Cites] J Neurooncol. 2003 May;63(1):55-61 [12814255.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):61-9 [8865004.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2195-201 [9626221.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • (PMID = 19557499.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Stockhammer F, Misch M, Koch A, Czabanka M, Plotkin M, Blechschmidt C, Tuettenberg J, Vajkoczy P: Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol; 2010 Dec;100(3):407-15
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
  • Previously, low-dose metronomic temozolomide in combination with cyclo-oxigenase 2 inhibitors has had a beneficial effect as first-line treatment for glioblastoma.
  • From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m(2) twice daily and 200 mg celecoxib.
  • Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Celecoxib. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Disease-Free Survival. Female. Fluorine Radioisotopes. Follow-Up Studies. Humans. Male. Methylation / drug effects. Middle Aged. Positron-Emission Tomography / methods. Retrospective Studies. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Tyrosine / analogs & derivatives

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4359; author reply 4359-60 [18779626.001]
  • [Cites] J Nucl Med. 2007 Apr;48(4):519-27 [17401087.001]
  • [Cites] J Nucl Med. 2008 May;49(5):730-7 [18413396.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1391-9 [18000822.001]
  • [Cites] Neurology. 2006 Feb 28;66(4):587-9 [16505319.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):272-82 [16613322.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):69-79 [18772354.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1220-7 [18580490.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):351-60 [15015668.001]
  • [Cites] Anticancer Drugs. 2003 Aug;14 (7):515-22 [12960735.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] Oncology. 2007;73(1-2):21-5 [18332649.001]
  • [Cites] J Neurooncol. 2008 Jun;88(2):205-10 [18317691.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):142-8 [10389990.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Acta Oncol. 2006;45(2):144-55 [16546859.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):452-6 [8123472.001]
  • [Cites] J Neurooncol. 2010 May;97(3):311-22 [19841865.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):792-800 [16550381.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44 [19277712.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1464-70 [15248032.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):219-20 [16292485.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 20446016.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cyclooxygenase 2 Inhibitors; 0 / Fluorine Radioisotopes; 0 / O-(3-fluoropropyl)tyrosine; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Tumor Suppressor Proteins; 42HK56048U / Tyrosine; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; JCX84Q7J1L / Celecoxib; YF1K15M17Y / temozolomide
  •  go-up   go-down


37. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W: Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys; 2010 Jul 1;77(3):670-6
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
  • PURPOSE: To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma.
  • PATIENTS AND METHODS: A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m(2) (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m(2)), maintenance TMZ starting at 150 mg/m(2) using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Combined Modality Therapy / methods. Confidence Intervals. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Germany. Humans. Indomethacin / administration & dosage. Karnofsky Performance Status. Male. Middle Aged. Prospective Studies. Survival Rate. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19836157.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; XXE1CET956 / Indomethacin
  •  go-up   go-down


38. Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P: Clinical significance of molecular biomarkers in glioblastoma. Can J Neurol Sci; 2010 Sep;37(5):625-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of molecular biomarkers in glioblastoma.
  • AIM: To review the impact of molecular biomarkers on response to therapy and survival in patients with primary glioblastoma (GBM).
  • [MeSH-major] Biomarkers / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Glioblastoma / diagnosis. Glioblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. DNA Methylation / drug effects. DNA Methylation / genetics. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Regression Analysis. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21059509.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


39. Martinez R, Rohde V, Schackert G: Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol; 2010 Feb;96(3):321-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.
  • One of the hallmarks of glioblastoma is its inherent tendency to recur.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glioblastoma / genetics. Mutation / genetics. PTEN Phosphohydrolase / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Am J Hum Genet. 2006 Nov;79(5):923-34 [17033968.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1264-8 [17272309.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):71-8 [18004504.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):934-41 [10551321.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] Hum Mutat. 2000;16(2):109-22 [10923032.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Mol Carcinog. 2000 Nov;29(3):143-50 [11108659.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):255-7 [11300334.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 1;132(1):20-4 [11801303.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):779-83 [12754350.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):82-90 [12784873.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1954-6 [14647431.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 May;75(5):723-6 [15090567.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6806-14 [15286718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):432-7 [1324297.001]
  • [Cites] Hum Genet. 1994 May;93(5):607-8 [8168846.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):813-8 [7947085.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):57-64 [7815080.001]
  • [Cites] J Neurooncol. 1994;21(2):151-7 [7861191.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):661-4 [8760309.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 19644652.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2811648
  •  go-up   go-down


40. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science; 2008 Sep 26;321(5897):1807-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated genomic analysis of human glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer.
  • These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854877 for PMID:18772396 [PharmGKB] .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]
  • [Cites] J Comput Chem. 2004 Oct;25(13):1605-12 [15264254.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] J Comp Neurol. 1973 Mar 15;148(2):211-6 [4700508.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Biotechniques. 2008 Jul;45(1):81-94 [18611170.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):508-12 [11981567.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2495-9 [8669813.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Mol Biol Evol. 1998 Dec;15(12):1674-84 [9866202.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):31-3 [16369550.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):360-70 [16575211.001]
  • [Cites] Methods Mol Biol. 2007;356:319-50 [16988414.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):709-14 [17050665.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):27-34 [17646934.001]
  • [Cites] Genome Res. 2007 Sep;17(9):1304-18 [17693572.001]
  • [Cites] Free Radic Biol Med. 2007 Oct 15;43(8):1197-207 [17854715.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Cell. 2008 May 2;133(3):523-36 [18423832.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • (PMID = 18772396.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NINDS NIH HHS / NS / NS052507; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R37 CA057345-13; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R37 CA057345-18; United States / NCI NIH HHS / CA / CA09547; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA062924-160017; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NCI NIH HHS / CA / CA057345-13; United States / NCI NIH HHS / CA / P50 CA062924-160017; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / CA11898; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA057345-18; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NINDS NIH HHS / NS / 5P50-NS-20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ NIHMS105586; NLM/ PMC2820389
  •  go-up   go-down


41. Zhang C, Yao Y, Wang Y, Chen Z, Wu J, Mao Y, Zhou L: Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor. Int J Neurosci; 2010 Dec;120(12):787-91
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor.
  • Brain stem gliomas are rare intracranial tumors, especially in adults.
  • Malignant or high-grade brain stem gliomas are usually associated with a very poor prognosis.
  • This case report documents an adolescent harboring brain stem glioblastoma who had complete radiological response to temozolomide after partial tumor resection and survived for more than 3 years.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / mortality
  • [MeSH-minor] Fatal Outcome. Humans. Male. Survival Rate / trends. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20946086.001).
  • [ISSN] 1563-5279
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


42. Luetjens G, Mirzayan MJ, Brandis A, Krauss JK: Exophytic giant cell glioblastoma of the medulla oblongata. J Neurosurg; 2009 Mar;110(3):589-93
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic giant cell glioblastoma of the medulla oblongata.
  • Giant cell glioblastoma is a rare variant within the spectrum of glioblastoma multiforme (GBM) tumors.
  • A giant cell glioblastoma may be associated with a better prognosis than the common type of GBM after combined treatment involving tumor resection and radiochemotherapy.
  • A giant cell glioblastoma may occur at various sites in the brain and spinal cord.
  • Histopathological examination of the tumor revealed the typical features of a giant cell glioblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Medulla Oblongata
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061354.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Karmakar S, Olive MF, Banik NL, Ray SK: Intracranial stereotaxic cannulation for development of orthotopic glioblastoma allograft in Sprague-Dawley rats and histoimmunopathological characterization of the brain tumor. Neurochem Res; 2007 Dec;32(12):2235-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial stereotaxic cannulation for development of orthotopic glioblastoma allograft in Sprague-Dawley rats and histoimmunopathological characterization of the brain tumor.
  • Glioblastoma is the most common brain tumor that causes significant mortality annually.
  • Limitations of the current therapeutic regimens warrant development of new techniques and treatment strategies in orthotopic animal model for better management of this devastating brain cancer.
  • There are only a few experimental orthotopic models of glioblastoma for pre-clinical testing.
  • In the present investigation, we successfully implanted rat C6 cells via intracranial stereotaxic cannulation in adult Sprague-Dawley rats for development and histoimmunopathological characterization of an advanced orthotopic glioblastoma allograft model, which could be useful for investigating the course of glioblastoma development as well as for testing efficacy of new therapeutic agents.
  • The orthotopic glioblastoma allograft was generated by intracerebral injection of rat C6 cells through a guide-cannula system and after 21 post-inoculation days the brain tumor was characterized by histoimmunopathological experiments.
  • Histological staining and immunofluorescent labelings for TERT, VEGF, Bcl-2, survivin, XIAP, and GFAP revealed the distinct characteristics of glioblastoma in C6 allograft, which could be useful as a target for treatment with emerging new therapeutic agents.
  • Our investigation indicated the successful development of intracranial cannulated orthotopic glioblastoma allograft in adult Sprague-Dawley rats, making it as a useful animal model of glioblastoma for pre-clinical evaluation of various therapeutic strategies for the management of glioblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasm Transplantation / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2007 Apr;12 (4):671-84 [17219050.001]
  • [Cites] J Clin Neurosci. 2002 Nov;9(6):668-71 [12604281.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jul;127(7):826-33 [12823036.001]
  • [Cites] Oncogene. 1998 Dec 24;17 (25):3247-59 [9916987.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100 [9588554.001]
  • [Cites] Neurol Res. 2006 Jul;28(5):532-7 [16808885.001]
  • [Cites] Brain Res. 2004 May 1;1006(2):150-6 [15051518.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Mar;6(2):147-80 [16529544.001]
  • [Cites] Neuroscience. 2006 Sep 1;141(3):1265-80 [16765523.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):157-61 [10328588.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7494-506 [15326475.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):60-4 [11823699.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8569-77 [11731444.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] Neurosci Lett. 2006 Oct 16;407(1):53-8 [16949208.001]
  • [Cites] J Neurochem. 2007 Jul;102(2):522-38 [17596214.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):225-32 [16187019.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):11-6 [10424775.001]
  • [Cites] J Neurovirol. 1999 Dec;5(6):538-55 [10602396.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):921-9; discussion 929-30 [11014432.001]
  • [Cites] J Neurochem. 2005 Jan;92(1):1-9 [15606891.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):641-55 [12209758.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2606-15 [15880378.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31 [9270488.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):532-8 [15685240.001]
  • [Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]
  • [Cites] J Neurooncol. 2001 May;52(3):205-15 [11519850.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Dec;12 (12 ):1899-924 [14640936.001]
  • [Cites] Neurosci Lett. 2007 Mar 30;415(3):242-7 [17335970.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6381-4 [15374943.001]
  • (PMID = 17701349.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR015455; United States / NINDS NIH HHS / NS / NS-57811; United States / NCI NIH HHS / CA / R01 CA-91460
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Coloring Agents
  •  go-up   go-down


44. Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS Jr: Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol; 2009 Aug;11(4):357-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
  • Classical immunotherapeutic approaches to glioblastoma multiforme (GBM) have shown mixed results, and therapies focused on innate lymphocyte activity against GBM have not been rigorously evaluated.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1989 Feb;70(2):175-82 [2643685.001]
  • [Cites] Cancer Immunol Immunother. 2008 Nov;57(11):1599-609 [18301889.001]
  • [Cites] J Neurooncol. 1990 Apr;8(2):173-88 [2193121.001]
  • [Cites] J Immunol. 1991 May 15;146(10):3289-97 [1827481.001]
  • [Cites] J Immunol. 1992 Jun 15;148(12):3847-56 [1602133.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):944-51 [8487077.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4014-9 [8358730.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):138-41 [8018525.001]
  • [Cites] Cancer Immunol Immunother. 1994 Sep;39(3):193-7 [7923250.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3704-12 [7706713.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):840-52 [8625188.001]
  • [Cites] Neurol Res. 1997 Apr;19(2):145-52 [9175143.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1066-76 [9185713.001]
  • [Cites] J Immunol Methods. 1997 Jun 23;205(1):19-28 [9236911.001]
  • [Cites] Cancer Immunol Immunother. 1997 Oct;45(2):77-87 [9390198.001]
  • [Cites] Science. 1998 Mar 13;279(5357):1737-40 [9497295.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):42-51 [9647171.001]
  • [Cites] Cancer Immunol Immunother. 1998 Oct;47(2):97-103 [9769118.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):633-43 [9815731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879-84 [10359807.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9172-9 [15604289.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5766-73 [15843579.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):94-9 [15756684.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):523-8 [15977644.001]
  • [Cites] J Immunol Methods. 2006 Jan 20;308(1-2):53-67 [16343526.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4235-43 [16547260.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4478-87 [16618775.001]
  • [Cites] Exp Cell Res. 2006 May 1;312(8):1265-76 [16434036.001]
  • [Cites] J Neurooncol. 1999;45(2):141-57 [10778730.001]
  • [Cites] Oncol Res. 2000;12(1):17-24 [11061342.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3827-37 [11090067.001]
  • [Cites] Gene Ther. 2000 Nov;7(21):1853-8 [11110418.001]
  • [Cites] Springer Semin Immunopathol. 2000;22(3):191-217 [11116953.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):121-37 [11245272.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] Cancer Immunol Immunother. 2002 Jan;50(11):625-37 [11807626.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):65-71 [12101264.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1236-40 [12133944.001]
  • [Cites] Immunology. 2002 Sep;107(1):28-38 [12225360.001]
  • [Cites] Pharmacol Ther. 2003 Apr;98(1):71-108 [12667889.001]
  • [Cites] J Invest Dermatol. 2003 May;120(5):829-34 [12713589.001]
  • [Cites] Blood. 2003 Jul 1;102(1):200-6 [12623838.001]
  • [Cites] J Interferon Cytokine Res. 2003 Jul;23(7):379-93 [14511464.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8996-9006 [14695218.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6 [15203102.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] J Immunother. 2004 Sep-Oct;27(5):398-404 [15314549.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):826-9 [3142970.001]
  • [Cites] Cytotherapy. 2006;8(2):118-29 [16698685.001]
  • [Cites] Cancer Immunol Immunother. 2006 Sep;55(9):1072-80 [16328383.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2078-85 [16973957.001]
  • [Cites] J Immunol Methods. 2007 Sep 30;326(1-2):63-75 [17716681.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):59-73 [18097448.001]
  • [Cites] J Neurosurg. 1989 Aug;71(2):169-74 [2787395.001]
  • (PMID = 19211933.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097247; United States / NCI NIH HHS / CA / P50 CA 097247-06A1; United States / NINDS NIH HHS / NS / R21 NS057431-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC2743216
  •  go-up   go-down


45. Ricci-Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, Petrucci G, Montano N, Maira G, De Maria R: Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ; 2008 Sep;15(9):1491-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal differentiation of glioblastoma stem cells.
  • Glioblastoma multiforme is a severe form of cancer most likely arising from the transformation of stem or progenitor cells resident in the brain.
  • Although the tumorigenic population in glioblastoma is defined as composed by cancer stem cells (CSCs), the cellular target of the transformation hit remains to be identified.
  • Subcutaneous injection of CSCs or single CSC clones from two of seven patients produced tumor xenografts containing osteo-chondrogenic areas in the context of glioblastoma-like tumor lesions.
  • The discovery of such biological properties might provide considerable information to the development of new therapeutic strategies aimed at forcing glioblastoma stem cell differentiation.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Mesoderm / cytology. Neoplastic Stem Cells / cytology
  • [MeSH-minor] Adult. Aged. Animals. Cell Differentiation. Clone Cells. Female. Humans. Male. Mice. Mice, SCID. Middle Aged. Neurons / cytology. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497759.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro JM: Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol; 2007 Nov;85(2):149-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme.
  • The role of stem cells in the origin, growth patterns, and infiltration of glioblastoma multiforme is a subject of intense investigation.
  • One possibility is that glioblastoma may arise from transformed stem cells in the ventricular zone.
  • To explore this hypothesis, we examined the distribution of two stem cell markers, activating transcription factor 5 (ATF5) and CD133, in an autopsy brain specimen from an individual with glioblastoma multiforme.
  • A 41-year-old male with a right posterior temporal glioblastoma had undergone surgery, radiation, and chemotherapy.
  • The brain was harvested within several hours after death.
  • To our knowledge, this is the first in situ demonstration of stem cell markers in whole human brain.
  • The robust staining for ATF5 and CD133 in histologically normal ventricular zone suggests that an increase in periventricular stem cell activity occurred in this patient on the side of the tumor, either as a localized response to brain injury or as an integral component of oncogenesis and tumor recurrence.
  • [MeSH-major] Activating Transcription Factors / metabolism. Antigens, CD / metabolism. Brain / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] AC133 Antigen. Adult. Biomarkers / metabolism. Cerebral Ventricles / metabolism. Fatal Outcome. Humans. Immunohistochemistry. Male. Tissue Distribution

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Sep;89(2):247-8; author reply 249 [18568293.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Acta Neuropathol. 1979 Mar 15;45(3):177-85 [442983.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] J Comp Neurol. 2006 Jan 20;494(3):415-34 [16320258.001]
  • [Cites] Mol Cell Neurosci. 2005 Jul;29(3):372-80 [15950153.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4590-600 [12805299.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 1966 Jun 25;210(5043):1378-9 [6007120.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):907-16 [16170340.001]
  • [Cites] J Neurosci. 2005 Apr 13;25(15):3889-99 [15829641.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Neurosci. 2005 Jan 5;25(1):10-8 [15634762.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Experientia. 1976 Nov 15;32(11):1467-8 [992001.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • (PMID = 17516028.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / ATF5 protein, human; 0 / Activating Transcription Factors; 0 / Antigens, CD; 0 / Biomarkers; 0 / Glycoproteins; 0 / PROM1 protein, human; 0 / Peptides
  •  go-up   go-down


47. Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW: Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res; 2010 Jan;30(1):253-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prognostic value of CD44 in glioblastoma multiforme.
  • BACKGROUND/AIM: Glioblastoma and astrocytoma are the most common brain tumors affecting adults 45-60 years of age.
  • The poor prognosis for glioblastoma patients results from recurrence after treatment.
  • PATIENTS AND METHODS: Microarray analyses of clinical specimens from glioblastoma patients were used to identify potential tumor markers.
  • [MeSH-major] Antigens, CD44 / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics
  • [MeSH-minor] Adult. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150644.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human
  •  go-up   go-down


48. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kim JY, Kim KW, Jung JS: Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett; 2007 Nov 18;257(2):172-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Wnt5a in the proliferation of human glioblastoma cells.
  • The functions of Wnt5a in human glioblastoma (GBM) have yet to be determined.
  • The results of immunohistochemical analyses have revealed that Wnt5a expression was higher in human GBM than in normal brain tissue and low-grade astrocytoma.
  • In order to assess the role of Wnt5a on proliferation in human glioblastoma cells, we employed U87MG and GBM-05, a newly established GBM cell line.
  • GBM-05 cells formed infiltrating brain tumors after being intracerebrally transplanted into nude mice, and xenotransplanted GBM-05 cells were observed to differentiate into neuronal and astrocyte lineages.
  • Wnt5a expression in the xenotransplanted tumors was higher than that detected in the surrounding brain tissues.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Proliferation. Glioblastoma / pathology. Proto-Oncogene Proteins / physiology. Wnt Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Blotting, Western. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Karyotyping. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Nerve Tissue Proteins / analysis. Nestin. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709179.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Proto-Oncogene Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins
  •  go-up   go-down


49. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K: An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand; 2008 Mar;117(3):191-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme.
  • Objectives - To explore the use of boron neutron capture therapy (BNCT) for patients with glioblastoma multiforme (GBM), recurring after surgery and conventional radiotherapy (photon radiotherapy).
  • Conclusions - Boron neutron capture therapy, with the prolonged procedure for infusion, is at least as effective as other radiation therapies for recurrent GBM and is delivered in one treatment session, with low radiation dose to the healthy brain.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Body Weight. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297764.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


50. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Serum samples from 61 newly diagnosed patients with brain tumours and 50 age- and sex-matched non-tumour controls were analysed by ELISA for circulating levels of interleukin-12 (IL-12p70 and p40) and interleukin-10 (IL-10); pivotal Th1 and Th2 cytokines, respectively.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • This study shows that patients with advanced primary intracranial malignancies have decreased circulating IL-12 and increased circulating IL-10, demonstrating that brain tumours have a major systemic effect on the immune system.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged


51. Roma AA, Prayson RA: Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol; 2005 Dec;9(6):307-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in 90 patients with glioblastoma multiforme.
  • Fascin immunohistochemical analysis was performed in 90 glioblastoma multiforme, including 53 males and 37 females (mean age, 58.3 years).
  • There was no obvious correlation with the extent of staining and survival among glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioblastoma / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / metabolism. Astrocytoma / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308158.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


52. Showalter TN, Andrel J, Andrews DW, Curran WJ Jr, Daskalakis C, Werner-Wasik M: Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):820-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal glioblastoma multiforme: prognostic factors and patterns of progression.
  • PURPOSE: To assess the progression patterns in patients with multifocal glioblastoma multiforme who had undergone whole brain radiotherapy (WBRT), the historical standard, versus three-dimensional conformal radiotherapy, and to identify predictive treatment and pretreatment factors.
  • METHODS AND MATERIALS: The records of 50 patients with multifocal glioblastoma multiforme treated with RT were reviewed.
  • On the basis of the progression pattern, we do not recommend WBRT as a mandatory component of the treatment of multifocal glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Cranial Irradiation / methods. Disease Progression. Humans. Middle Aged. Prognosis. Proportional Hazards Models. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1335; author reply 1335 [17967325.001]
  • (PMID = 17499453.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Iacob G, Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life; 2009 Oct-Dec;2(4):386-93
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current data and strategy in glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors.
  • Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Chromosome Mapping. Diagnosis, Differential. Gene Amplification. Humans. Middle Aged. Mutation. Oncogenes. PTEN Phosphohydrolase / deficiency. PTEN Phosphohydrolase / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Sep;3(9):E1 [17805242.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Hum Gene Ther. 2003 Sep 1;14(13):1247-54 [12952596.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):1-8 [14712205.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 [15184253.001]
  • [Cites] J Neurosurg. 1976 Apr;44(4):442-8 [176331.001]
  • [Cites] Nature. 1980 Dec 25;288(5792):724-7 [6256643.001]
  • [Cites] Carcinogenesis. 1985 Jun;6(6):883-6 [4006075.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;42:187-92 [3189008.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 25;17(16):6581-90 [2780288.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):323-31 [1686725.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79 [7673356.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):453-61 [9509295.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):79-89 [15847978.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):198-206 [15865885.001]
  • [Cites] Neurologist. 2005 Nov;11(6):362-5 [16286879.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):337-43 [16520474.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):1025-34 [18667747.001]
  • [Cites] J Med Life. 2009 Oct-Dec;2(4):386-93 [20108752.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • (PMID = 20108752.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC3019011
  •  go-up   go-down


54. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C: Glioblastoma multiforme with long term survival. Neurol India; 2005 Sep;53(3):329-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme with long term survival.
  • Glioblastoma multiforme (GBM) Patients generally have a dismal prognosis, with median survival of 10-12 months.
  • [MeSH-major] Glioblastoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Survivors


55. Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O: Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. J Neurooncol; 2009 Jan;91(2):213-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.
  • INTRODUCTION: We investigated the effect of increased tumor perfusion using dynamic susceptibility-contrast magnetic resonance imaging (DSC-MRI) in glioblastoma (GBM) patients on the surrounding ipsilateral brain tissue with respect to perfusion of the normal, unaffected contralateral brain and of the tumor.
  • MATERIAL AND METHODS: DSC-MRI was performed in 11 patients with glioblastoma using a multislice T2*-weighed EPI sequence (TR/TE = 2,000/62 ms; FOV 240 mm; matrix 128 x 128; slice thickness 6 mm) on a standard clinical 1.5 Tesla scanner during intravenous injection of 40 cc Gadolinium-DTPA at a flow rate of 5 cc/s.
  • RESULTS: Relative CBV and CBF were significantly higher in gray matter than in the respective white matter (paired t-test; P < 0.001) with a high correlation for both perfusion parameters between the gray and the white matter in both ipsilateral and contralateral brain (P < 0.001).
  • This increased perfusion of the tumor is not at the expense of perfusion of the ipsilateral normal brain parenchyma and in fact, the rCBV and rCBF values are linked to tumor-induced changes in rCBV and rCBF.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Connective Tissue / pathology. Functional Laterality. Glioblastoma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cerebrovascular Circulation. Contrast Media. Female. Humans. Male. Middle Aged. Perfusion

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):881-90 [10815664.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Adv Exp Med Biol. 2003;530:347-57 [14562730.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] Acad Radiol. 2001 May;8(5):384-91 [11345268.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Magn Reson Med. 2000 Jun;43(6):845-53 [10861879.001]
  • [Cites] Neuroimage. 2005 Jan 1;24(1):1-11 [15588591.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(5):396-402 [1716257.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):891-9 [10815665.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):697-703 [16261571.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):300-5 [9950501.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):156-65 [16533757.001]
  • [Cites] Histopathology. 2001 Oct;39(4):409-15 [11683943.001]
  • [Cites] Radiology. 2006 Feb;238(2):658-67 [16396838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):53-8 [10924971.001]
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] Magn Reson Imaging. 1985;3(1):27-35 [2987640.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):710-7 [16261573.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] Radiology. 1999 Feb;210(2):519-27 [10207439.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):353-7; discussion 357-8 [11220379.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neuroradiology. 2002 Oct;44(10):806-11 [12389127.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):718-22 [16261569.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):402-8 [16484419.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):134-45 [12784879.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Neuroimage. 2006 Aug 15;32(2):489-97 [16806983.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):693-6 [16261568.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 [16611779.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 18807224.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


56. Taha M, Ahmad A, Wharton S, Jellinek D: Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis. Br J Neurosurg; 2005 Aug;19(4):348-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis.
  • We present an unusual case of extracranial metastasis of glioblastoma multiforme (GBM) to the parotid gland and cervical lymph nodes.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Parotid Neoplasms / secondary. Parotitis / etiology
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455543.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, Dimeco F, Milanesi IM, Erbetta A, Boiardi A, Fariselli L, Salmaggi A: Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol; 2009 Aug;94(1):57-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.
  • BACKGROUND: The prognosis of patients with glioblastoma is very poor with a mean survival of 10-12 months.
  • However, these have been shown to improve survival only marginally in glioblastoma multiforme (GBM) patients.
  • METHODS: A retrospective analysis on 160 adult patients (> or =16 years) treated for histologically confirmed GBM between 2003 and 2005 at our Institution was performed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / therapeutic use. Cisplatin / therapeutic use. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2004 Jul;6(3):247-52 [15279717.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12 ):937-44 [16321761.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] J Neurooncol. 2008 May;88(1):43-50 [18231723.001]
  • [Cites] Ital J Neurol Sci. 1992 May;13(4):311-5 [1318287.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):71-5 [11131989.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Eur J Cancer. 1991;27(7):852-6 [1834116.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12 (15):4523-32 [16899598.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):664-71 [10900246.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1275-80 [16211296.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1712-6 [15073861.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1305-9 [16525186.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1079-99 [17485253.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1337-44 [18213621.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3871-9 [16921039.001]
  • [Cites] Oncol Res. 2007;16(10):453-63 [18196869.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):203-8 [15015788.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 19212704.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


58. Tunca B, Bekar A, Cecener G, Egeli U, Vatan O, Tolunay S, Kocaeli H, Aksoy K: Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neurooncol; 2007 May;82(3):263-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) represents the most common and aggressive type of primary neoplasms of the central nervous system.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Mutation. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Turkey

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7033-8 [11156408.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3937-43 [11051241.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):89-94 [11083071.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Hum Mol Genet. 2005 Aug 15;14 (16):2459-68 [16014636.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):450-4 [14623110.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7 [10468583.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):12-8 [16410744.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23 ):12479-84 [9356475.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 [14734474.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • (PMID = 17151929.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human
  •  go-up   go-down


59. Herrlinger U, Rieger J, Steinbach JP, Nägele T, Dichgans J, Weller M: UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol; 2005 Feb;71(3):295-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.
  • Glioblastoma is a highly angiogenic tumor with a dismal prognosis.
  • We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):41-4 [10695820.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):73-80 [11863115.001]
  • [Cites] Arthritis Rheum. 1989 Sep;32(9):1065-73 [2476134.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1195-206 [11181686.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4C):2977-80 [9713495.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):427-36 [11693902.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(4):251-6 [1702913.001]
  • (PMID = 15735920.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


60. Tchirkov A, Sapin V, Marceau G, Chautard E, Narla G, Veronese L, Friedman S, Khalil T, Vago P, Kemeny JL, Verrelle P: Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem Lab Med; 2010 Aug;48(8):1167-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma.
  • Glioblastoma multiforme (GBM) is the most aggressive form of these primary brain tumors.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545576.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 0 / KLF6 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger
  •  go-up   go-down


61. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT: Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):704-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic analyses for predictors of radiation response in glioblastoma.
  • PURPOSE: Radiotherapy (RT) for patients with glioblastoma improves survival and is recommended for nearly all patients with this diagnosis.
  • It has been previously reported that epidermal growth factor receptor (EGFR) gene amplification and TP53 mutation correlate with the response to RT in patients with glioblastoma.
  • METHODS AND MATERIALS: We sought to identify molecular markers that could predict the response to RT, progression-free survival after RT, and overall survival among 75 glioblastoma patients treated with RT at a single institution.
  • However, in accordance with recent observations that the prognostic effects of genetic alterations in glioblastoma may depend on patient age, we observed age-dependent prognostic effects of TP53 and CDKN2A/p16 alterations in our patient population.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / radiotherapy. Glioblastoma / genetics. Glioblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Disease-Free Survival. Female. Gene Amplification. Gene Deletion. Genes, p16. Genes, p53 / genetics. Genetic Markers. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978739.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


62. Bohman LE, Gallardo J, Hankinson TC, Waziri AE, Mandigo CE, McKhann GM 2nd, Sisti MB, Canoll P, Bruce JN: The survival impact of postoperative infection in patients with glioblastoma multiforme. Neurosurgery; 2009 May;64(5):828-34; discussion 834-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The survival impact of postoperative infection in patients with glioblastoma multiforme.
  • METHODS: A single-center operative experience accumulated over 10 years was examined to evaluate whether postoperative infections conferred a survival advantage in patients with glioblastoma multiforme.
  • CONCLUSION: In this single-center study, postoperative infection did not confer any survival advantage in patients with glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Glioblastoma / mortality. Neurosurgical Procedures / adverse effects. Postoperative Complications / mortality
  • [MeSH-minor] Adult. Aged. Bacterial Infections / classification. Bacterial Infections / etiology. Bacterial Infections / mortality. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404146.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, Razavi P, Patoka J, Wiencke JK, Bondy ML, Wrensch M: Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1118-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between polymorphisms in DNA repair genes and glioblastoma.
  • A pooled analysis was conducted to examine the association between select variants in DNA repair genes and glioblastoma multiforme, the most common and deadliest form of adult brain tumors.
  • Genetic data for approximately 1,000 glioblastoma multiforme cases and 2,000 controls were combined from four centers in the United States that have conducted case-control studies on adult glioblastoma multiforme, including the National Cancer Institute, the National Institute for Occupational Safety and Health, the University of Texas M. D.
  • The C allele of the PARP1 rs1136410 variant was associated with a 20% reduction in risk for glioblastoma multiforme (odds ratio(CT or CC), 0.80; 95% confidence interval, 0.67-0.95).
  • A 44% increase in risk for glioblastoma multiforme was found for individuals homozygous for the G allele of the PRKDC rs7003908 variant (odds ratio(GG), 1.44; 95% confidence interval, 1.13-1.84); there was a statistically significant trend (P = 0.009) with increasing number of G alleles.
  • Few studies have reported on the associations between variants in DNA repair genes and brain tumors, and few specifically have examined their impact on glioblastoma multiforme.
  • Our results suggest that common variation in DNA repair genes may be associated with risk for glioblastoma multiforme.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7136-41 [16627622.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):145-55 [16598069.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):197-205 [17200355.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):122-6 [17214964.001]
  • [Cites] Neuroscience. 2007 Apr 14;145(4):1267-72 [17084037.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1906-13 [17389609.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):1-5 [17999957.001]
  • [Cites] Hum Mol Genet. 2008 Mar 15;17(6):800-5 [18048407.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):484-9 [18349266.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1368-73 [18559551.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7 [10952103.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Genet Epidemiol. 2001 Feb;20(2):258-70 [11180451.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Maturitas. 2001 Feb 28;38(1):17-22; discussion 22-3 [11311581.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] Neurology. 2001 Nov 27;57(10):1751-5 [11723257.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):22-33 [11900249.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Toxicology. 2003 Nov 15;193(1-2):3-34 [14599765.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4378-84 [15205355.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5560-3 [15313891.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6344-8 [15342424.001]
  • [Cites] Cell. 1986 Mar 28;44(6):913-23 [2420469.001]
  • [Cites] Nucleic Acids Res. 1987 Nov 25;15(22):9195-213 [3684592.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Cells. 1990 Oct;2(10):311-20 [2282248.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4760-3 [8062276.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2415-8 [7852297.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1261-6 [7882319.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):17-23 [8583241.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8285-94 [8626523.001]
  • [Cites] Methods Enzymol. 1996;272:199-210 [8791778.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 1;100(1):77-83 [9406586.001]
  • [Cites] Environ Mol Mutagen. 1999;33(1):3-20 [10037319.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Genome Res. 2005 Feb;15(2):269-75 [15687290.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):722-6 [15705867.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2363-72 [15834925.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):495-507 [16212814.001]
  • [Cites] Am J Hum Genet. 2006 Jan;78(1):15-27 [16385446.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • (PMID = 19318434.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA070917; United States / NCI NIH HHS / CA / R01 CA052689-18; United States / NCI NIH HHS / CA / R01 CA052689-19; United States / NCI NIH HHS / CA / CA097257-080001; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / CA052689-19; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA070917; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA52689; United States / NCI NIH HHS / CA / P50 CA097257-080001; United States / NCI NIH HHS / CA / R01 CA070917-09; United States / NCI NIH HHS / CA / CA052689-18; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS96659; NLM/ PMC2667563
  •  go-up   go-down


64. Yuile P, Dent O, Cook R, Biggs M, Little N: Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. J Clin Neurosci; 2006 Aug;13(7):747-51
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables.
  • This retrospective study of 133 patients with glioblastoma multiforme evaluates survival times post-radiation in patients stratified in respect to age, presenting symptoms, tumour location, extent of surgery, and radiation dose delivered.
  • Presenting features were coded as seizure, loss of consciousness, headache, speech or visual disturbance, weakness and confusion, as were tumour sites within the brain.
  • Other parameters assessed included side of brain, age, extent of surgery and radiation dose.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy. Neurosurgery / methods. Radiotherapy / methods. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908158.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


65. Ali K, Lu Y, Das U, Sharma RK, Wiebe S, Meguro K, Sadanand V, Fourney DR, Vitali A, Kelly M, May T, Gomez J, Pellerin E: Biomolecular diagnosis of human glioblastoma multiforme using Synchrotron mid-infrared spectromicroscopy. Int J Mol Med; 2010 Jul;26(1):11-6
Hazardous Substances Data Bank. CALCIUM FLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomolecular diagnosis of human glioblastoma multiforme using Synchrotron mid-infrared spectromicroscopy.
  • Glioblastoma multiforme (GBM) is one of the most malignant human tumors, with a uniformly poor outcome.
  • One obstacle in curing malignant brain tumors is the limitation of conventional light microscopy in detecting microscopic residual tumor in biopsy samples from the perimeter of the surgically resected tumor.
  • Compared with molecular signatures obtained from normal control brain tissue, unique spectroscopic patterns were detected in GBM tumor samples from 6 patients.
  • Corroboration of these findings in a larger number of GBM may allow for more precise identification of these and other types of brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Spectrophotometry, Infrared / methods. Synchrotrons
  • [MeSH-minor] Adult. Aged. Calcium Fluoride / chemistry. Child. Cluster Analysis. Cryoultramicrotomy / methods. Female. Histocytochemistry / methods. Humans. Lipids / analysis. Lipids / chemistry. Male. Middle Aged. Proteins / analysis. Proteins / chemistry

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514416.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Lipids; 0 / Proteins; O3B55K4YKI / Calcium Fluoride
  •  go-up   go-down


66. Yamamoto T, Nakai K, Kageji T, Kumada H, Endo K, Matsuda M, Shibata Y, Matsumura A: Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol; 2009 Apr;91(1):80-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for newly diagnosed glioblastoma.
  • PURPOSE: The efficacy, safety, and dose distribution of neutron capture therapy (NCT) were evaluated in 15 patients with newly diagnosed glioblastoma.
  • Three protocol-1 patients and one protocol-2 patient suffered transient orbital swelling accompanied by double vision (Grade 2); one of the three protocol-1 patients suffered post-epileptic brain swelling (Grade 4) requiring surgical intervention.
  • CONCLUSION: It is suggested that NCT is effective for survival of newly diagnosed glioblastoma with acceptable adverse effects.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285355.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


67. Saidi A, Javerzat S, Bellahcène A, De Vos J, Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A, Hagedorn M: Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer; 2008 May 15;122(10):2187-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.
  • In glioblastoma patients, these genes showed coregulation and their expression differed significantly from low-grade glioma.
  • Elafin-positive tumor cells were only found in glioblastoma, where they were clustered around necrotic areas.
  • Our results indicate that anti-angiogenesis in experimental glioma drives expression of critical genes which relate to disease aggressiveness in glioblastoma patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gene Expression Regulation, Neoplastic. Glioblastoma / blood supply. Glioblastoma / mortality. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adipokines. Adult. Astrocytoma / blood supply. Astrocytoma / metabolism. Astrocytoma / mortality. Brain / metabolism. Brain / pathology. Brain Neoplasms / blood supply. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Cell Proliferation. Elafin / metabolism. Female. Gene Expression Profiling. Glycoproteins / metabolism. Humans. Immunoenzyme Techniques. Lectins. Male. Middle Aged. Neovascularization, Pathologic. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Up-Regulation

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [CommentIn] Int J Cancer. 2009 Mar 15;124(6):1492-4 [19089918.001]
  • (PMID = 18092325.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Elafin; 0 / Glycoproteins; 0 / Lectins; 0 / PI3 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


68. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med; 2005 Mar 10;352(10):987-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
  • BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal.
  • The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy.
  • METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
  • CONCLUSIONS: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Radiotherapy, Computer-Assisted / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938011.001]
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938012.001]
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938013.001]
  • (PMID = 15758009.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


69. Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, Berger MS, Chang SM: Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg; 2005 Apr;102(4):622-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults.
  • OBJECT: The clinical outcome and treatment of adult patients with disseminated intracranial glioblastoma multiforme (GBM) is unclear.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871503.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13525; United States / NCI NIH HHS / CA / CA82103; United States / NINDS NIH HHS / NS / NS42927
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


70. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med; 2008 Jun 24;6:14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
  • BACKGROUND: Glioblastoma multiforme (GBM) is an invariably fatal central nervous system tumor despite treatment with surgery, radiation, and chemotherapy.
  • In this study, we investigated the role of microRNAs in regulating the differentiation and proliferation of neural stem cells and glioblastoma-multiforme tumor cells.
  • METHODS: We used quantitative RT-PCR to assess microRNA expression in high-grade astrocytomas and adult mouse neural stem cells.
  • To assess the function of candidate microRNAs in high-grade astrocytomas, we transfected miR mimics to cultured-mouse neural stem cells, -mouse oligodendroglioma-derived stem cells, -human glioblastoma multiforme-derived stem cells and -glioblastoma multiforme cell lines.
  • RESULTS: Our studies revealed that expression levels of microRNA-124 and microRNA-137 were significantly decreased in anaplastic astrocytomas (World Health Organization grade III) and glioblastoma multiforme (World Health Organization grade IV) relative to non-neoplastic brain tissue (P < 0.01), and were increased 8- to 20-fold during differentiation of cultured mouse neural stem cells following growth factor withdrawal.
  • Expression of microRNA-137 was increased 3- to 12-fold in glioblastoma multiforme cell lines U87 and U251 following inhibition of DNA methylation with 5-aza-2'-deoxycytidine (5-aza-dC).
  • Transfection of microRNA-124 or microRNA-137 induced morphological changes and marker expressions consistent with neuronal differentiation in mouse neural stem cells, mouse oligodendroglioma-derived stem cells derived from S100 beta-v-erbB tumors and cluster of differentiation 133+ human glioblastoma multiforme-derived stem cells (SF6969).
  • Transfection of microRNA-124 or microRNA-137 also induced G1 cell cycle arrest in U251 and SF6969 glioblastoma multiforme cells, which was associated with decreased expression of cyclin-dependent kinase 6 and phosphorylated retinoblastoma (pSer 807/811) proteins.
  • CONCLUSION: microRNA-124 and microRNA-137 induce differentiation of adult mouse neural stem cells, mouse oligodendroglioma-derived stem cells and human glioblastoma multiforme-derived stem cells and induce glioblastoma multiforme cell cycle arrest.
  • These results suggest that targeted delivery of microRNA-124 and/or microRNA-137 to glioblastoma multiforme tumor cells may be therapeutically efficacious for the treatment of this disease.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2006 Apr;13(7):646-51 [16341056.001]
  • [Cites] RNA. 2006 Feb;12(2):187-91 [16373485.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Technol Cancer Res Treat. 2006 Jun;5(3):261-9 [16700622.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):205-14 [16723630.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6156-62 [17028594.001]
  • [Cites] Mol Pharm. 2006 Nov-Dec;3(6):726-36 [17140260.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):20-8 [17018695.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7261-70 [17189397.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):39-58, viii [17244553.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1424-9 [17308079.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):531-6 [17344415.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2456-68 [17363563.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1167-74 [17363510.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Genes Dev. 2007 Apr 1;21(7):744-9 [17403776.001]
  • [Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):435-48 [17679093.001]
  • [Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8994-9000 [17908999.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):112-20 [18287341.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] RNA. 2003 Oct;9(10):1274-81 [13130141.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):217-8 [14528306.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):215-7 [14528307.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):29-36 [14603439.001]
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Eur J Neurosci. 2005 Mar;21(6):1469-77 [15845075.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):974-8 [15944714.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):857-64 [16357340.001]
  • [Cites] Cell Cycle. 2006 Feb;5(3):266-70 [16410727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9353-8 [15961540.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12135-40 [16099834.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1267-77 [16377567.001]
  • [CommentIn] BMC Med. 2008;6:15 [18577221.001]
  • (PMID = 18577219.001).
  • [ISSN] 1741-7015
  • [Journal-full-title] BMC medicine
  • [ISO-abbreviation] BMC Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS028478; United States / NINDS NIH HHS / NS / NS28478; United States / NCI NIH HHS / CA / K01 CA101777; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / CA101777; United States / NINDS NIH HHS / NS / R37 NS028478
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN124 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2443372
  •  go-up   go-down


71. Schwartzbaum JA, Xiao Y, Liu Y, Tsavachidis S, Berger MS, Bondy ML, Chang JS, Chang SM, Decker PA, Ding B, Hepworth SJ, Houlston RS, Hosking FJ, Jenkins RB, Kosel ML, McCoy LS, McKinney PA, Muir K, Patoka JS, Prados M, Rice T, Robertson LB, Schoemaker MJ, Shete S, Swerdlow AJ, Wiemels JL, Wiencke JK, Yang P, Wrensch MR: Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis; 2010 Oct;31(10):1770-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited variation in immune genes and pathways and glioblastoma risk.
  • To determine whether inherited variations in immune function single-nucleotide polymorphisms (SNPs), genes or pathways affect glioblastoma risk, we analyzed data from recent genome-wide association studies in conjunction with predefined immune function genes and pathways.
  • Gene and pathway analyses were conducted on two independent data sets using 6629 SNPs in 911 genes on 17 immune pathways from 525 glioblastoma cases and 602 controls from the University of California, San Francisco (UCSF) and a subset of 6029 SNPs in 893 genes from 531 cases and 1782 controls from MD Anderson (MDA).
  • Although three correlated epidermal growth factor receptor (EGFR) SNPs were consistently associated with glioblastoma in all four data sets (Mantel-Haenzel P values = 1 × 10⁻⁵ to 4 × 10⁻³), independent replication is required as genome-wide significance was not attained.
  • In gene-level analyses, eight immune function genes were significantly (minP < 0.05) associated with glioblastoma; the IL-2RA (CD25) cytokine gene had the smallest minP values in both UCSF (minP = 0.01) and MDA (minP = 0.001) data sets.
  • The IL-2RA receptor is found on the surface of regulatory T cells potentially contributing to immunosuppression characteristic of the glioblastoma microenvironment.
  • In pathway correlation analyses, cytokine signaling and adhesion-extravasation-migration pathways showed similar associations with glioblastoma risk in both MDA and UCSF data sets.
  • Our findings represent the first systematic description of immune genes and pathways that characterize glioblastoma risk.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genet Epidemiol. 2002 Feb;22(2):170-85 [11788962.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2551-9 [12855630.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]
  • [Cites] Genet Epidemiol. 2003 Dec;25(4):360-6 [14639705.001]
  • [Cites] Curr Allergy Asthma Rep. 2004 Jan;4(1):65-73 [14680625.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1131-9 [15191930.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1464-5 [14962934.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6459-65 [16024651.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7306-15 [17189402.001]
  • [Cites] Am J Hum Genet. 2007 Feb;80(2):353-60 [17236140.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):95-105 [17315190.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1229-35 [17548690.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]
  • [Cites] Eur J Epidemiol. 2007;22(9):647-64 [17636416.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50 [17925535.001]
  • [Cites] PLoS One. 2007;2(10):e1035 [17940599.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):867-90, vii [17964019.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2448-54 [18006935.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2543-7 [17916900.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):310-5 [18264096.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1277-81 [18483351.001]
  • [Cites] Genet Epidemiol. 2008 Sep;32(6):560-6 [18428428.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1938-43 [18676680.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6640-6 [18927306.001]
  • [Cites] Cancer Causes Control. 2009 Feb;20(1):87-96 [18766447.001]
  • [Cites] Semin Cancer Biol. 2009 Apr;19(2):92-6 [19049876.001]
  • [Cites] J Clin Neurosci. 2009 Jun;16(6):748-54 [19324552.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8 [19423540.001]
  • [Cites] Semin Radiat Oncol. 2009 Jul;19(3):163-70 [19464631.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1257-65 [19499547.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):905-8 [19578366.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):899-904 [19578367.001]
  • [Cites] Clin Exp Allergy. 2009 Sep;39(9):1314-23 [19538496.001]
  • [Cites] Lung Cancer. 2009 Oct;66(1):114-9 [19201048.001]
  • [Cites] Immunity. 2009 Sep 18;31(3):438-49 [19766086.001]
  • [Cites] Am J Hum Genet. 2010 Jan;86(1):6-22 [20074509.001]
  • [Cites] Bioinformatics. 2010 Feb 15;26(4):445-55 [20053841.001]
  • [Cites] Neuro Oncol. 2010 Apr;12(4):320-7 [20308310.001]
  • [Cites] Mol Biol Rep. 2010 Jun;37(5):2149-56 [19669929.001]
  • [Cites] Acta Oncol. 2010 Aug;49(6):767-75 [20446891.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):34-41 [16155052.001]
  • [Cites] Semin Cancer Biol. 2006 Apr;16(2):98-105 [16378733.001]
  • [Cites] Curr Opin Immunol. 2006 Apr;18(2):214-9 [16464567.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4531-41 [16618782.001]
  • [Cites] Blood. 2006 May 15;107(10):3940-9 [16410445.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):234-43 [16723631.001]
  • [Cites] Genet Epidemiol. 2006 Sep;30(6):495-507 [16755536.001]
  • [Cites] Neurology. 2006 Sep 12;67(5):872-4 [16885506.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4272-6 [11970966.001]
  • (PMID = 20668009.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / 5R01 CA119215; United States / NCI NIH HHS / CA / R25 CA112355; United Kingdom / Cancer Research UK / / C1298/A8362; United States / NCI NIH HHS / CA / R25 CA 112355; United States / NCI NIH HHS / CA / 5R01 CA070917; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA070917; United States / NCI NIH HHS / CA / R01CA122163; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01 CA119215; United States / NCI NIH HHS / CA / R01CA52689; United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / R01 CA122163; United Kingdom / Wellcome Trust / / ; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ PMC2950934
  •  go-up   go-down


72. Rosati A, Marconi S, Pollo B, Tomassini A, Lovato L, Maderna E, Maier K, Schwartz A, Rizzuto N, Padovani A, Bonetti B: Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol; 2009 Jul;93(3):319-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels.
  • PURPOSE: The hypothesis addressed by this study is that a glutamine synthetase (GS) deficiency in neoplastic astrocytes is a possible molecular basis associated with seizure generation in glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / enzymology. Epilepsy / enzymology. Epilepsy / etiology. Glioblastoma / complications. Glioblastoma / enzymology. Glutamate-Ammonia Ligase / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Experientia. 1982 Oct 15;38(10):1199-202 [6128246.001]
  • [Cites] Glia. 2000 Oct;32(1):15-24 [10975907.001]
  • [Cites] Acta Psychiatr Neurol Scand Suppl. 1952;81:1-149 [14933179.001]
  • [Cites] Epilepsy Res. 1998 Sep;32(1-2):286-303 [9761328.001]
  • [Cites] Comp Biochem Physiol C. 1989;94(2):399-404 [2576778.001]
  • [Cites] Epilepsy Res Suppl. 1996;11:9-16 [9294725.001]
  • [Cites] Science. 1977 Mar 25;195(4284):1356-8 [14400.001]
  • [Cites] Neuropathol Appl Neurobiol. 1982 May-Jun;8(3):227-36 [6126838.001]
  • [Cites] Lancet. 2004 Jan 3;363(9402):28-37 [14723991.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Brain Res Mol Brain Res. 1989 Dec;6(4):223-32 [2574402.001]
  • [Cites] J Neurocytol. 2002 Sep-Nov;31(8-9):681-92 [14501207.001]
  • [Cites] Epilepsy Res. 1996 Dec;26(1):163-75 [8985698.001]
  • [Cites] J Neurosci Res. 1999 Aug 15;57(4):417-28 [10440891.001]
  • [Cites] Epilepsia. 2003 Sep;44(9):1223-32 [12919395.001]
  • [Cites] Neurol Clin. 2001 May;19(2):237-50 [11358743.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Eur J Pharmacol. 2002 Jul 5;447(2-3):227-37 [12151014.001]
  • [Cites] Lancet. 1993 Jun 26;341(8861):1607-10 [8099987.001]
  • [Cites] Dev Neurosci. 1988;10(1):47-56 [2897279.001]
  • [Cites] Epilepsia. 2002 Jul;43(7):703-10 [12102672.001]
  • [Cites] Brain Res. 2005 May 24;1044(2):190-6 [15885217.001]
  • [Cites] No To Shinkei. 1993 Apr;45(4):362-8 [8101449.001]
  • [Cites] Brain Res. 1982 May;256(1):3-11 [6124308.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):49-52 [14765386.001]
  • [Cites] Neurochem Int. 2002 Aug-Sep;41(2-3):123-42 [12020613.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Jun;16(3):205-11 [1976235.001]
  • (PMID = 19183851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.1.2 / Glutamate-Ammonia Ligase
  •  go-up   go-down


73. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res; 2008 Jul 15;68(14):5955-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
  • Therapeutic vaccination represents an intriguing additional therapy for glioblastoma multiforme (GBM; grade 4 glioma), which has a dismal prognosis and treatment response, but only early phase I vaccine trial results have been reported.
  • [MeSH-major] Brain Neoplasms / microbiology. Brain Neoplasms / therapy. Glioblastoma / immunology. Glioblastoma / therapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Cancer Vaccines. Dendritic Cells / immunology. Female. Humans. Immune System. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632651.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


74. Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L: Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys; 2005 Jul 15;62(4):1133-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
  • PURPOSE: In this study, we assess the efficacy of GliaSite brachytherapy in the treatment of patients with recurrent glioblastoma multiforme (GBM).
  • METHODS AND MATERIALS: Between 1999 and 2004, 24 patients with recurrent glioblastoma multiforme were treated with the GliaSite Radiation Therapy System (RTS).
  • CONCLUSIONS: GliaSite radiotherapy confers a prolongation of survival in patients with recurrent glioblastoma multiforme compared to historical controls with recurrent GBM.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Benzenesulfonates / therapeutic use. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Radiotherapy Dosage. Reoperation. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990019.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Iodine Radioisotopes; 0 / iotrex
  •  go-up   go-down


75. Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, Gutberlet M, Jordan A, Felix R, Wust P: 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperthermia; 2006 Jun;22(4):319-25
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma.
  • MATERIALS AND METHODS: Eleven patients with glioblastoma recurrences underwent MR and FET-PET imaging for planning of the nano cancer therapy.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy. Hyperthermia, Induced / methods. Magnetics. Nanostructures. Neoplasm Recurrence, Local / therapy. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy Planning, Computer-Assisted

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754352.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 42HK56048U / Tyrosine
  •  go-up   go-down


76. Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K, Miyata S, Nonoguchi N, Michiue H, Takahashi M, Inomata T, Imahori Y, Kirihata M, Sakurai Y, Maruhashi A, Kumada H, Ono K: Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res; 2009 Jan;50(1):51-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for newly diagnosed glioblastoma.
  • We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT).
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18957828.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


77. Aoyanagi E, Sasai K, Nodagashira M, Wang L, Nishihara H, Ihara H, Ikeda Y, Tanaka S: Clinicopathologic application of lectin histochemistry: bisecting GlcNAc in glioblastoma. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):518-25
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic application of lectin histochemistry: bisecting GlcNAc in glioblastoma.
  • Thus, discovering aberrant glycosylation patterns that serve as markers for brain tumor progression and metastasis represents an attractive strategy to improve clinicopathologic diagnosis and to provide aids to the development of novel therapies.
  • To identify glioblastoma (GBM) cells expressing glycoproteins that contain high levels of the bisecting N-acetylglucosamine (GlcNAc) structures, lectin histochemistry was carried out using erythroagglutinating phytohemagglutinin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661133.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Membrane Glycoproteins; 0 / Phytohemagglutinins; 0 / erythroagglutinating phytohemagglutinin; EC 2.4.1.- / N-Acetylglucosaminyltransferases; V956696549 / Acetylglucosamine
  •  go-up   go-down


78. Gross MW, Altscher R, Brandtner M, Haeusser-Mischlich H, Chiricuta IC, Siegmann AD, Engenhart-Cabillic R: Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. Clin Neurol Neurosurg; 2005 Apr;107(3):207-13
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
  • BACKGROUND: Due to its radioresistance, the prognosis of glioblastoma multiforme (GBM) remains poor.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Humans. Male. Middle Aged. Pilot Projects. Prospective Studies. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823676.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


79. Sarissky M, Lavicka J, Kocanová S, Sulla I, Mirossay A, Miskovsky P, Gajdos M, Mojzis J, Mirossay L: Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells. Neoplasma; 2005;52(4):352-9
Hazardous Substances Data Bank. DIAZEPAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells.
  • Glioblastoma multiforme (GBM) is neoplasm which is resistant to all currently used treatment modalities including surgery, radiation therapy and chemotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Brain Neoplasms / pathology. Diazepam / pharmacology. GABA Modulators / pharmacology. Glioblastoma / pathology. Perylene / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Drug Interactions. Female. Flow Cytometry. Humans. Male. Middle Aged. Photochemotherapy. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059654.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GABA Modulators; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; Q3JTX2Q7TU / Diazepam
  •  go-up   go-down


80. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, Gutin PH: Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery; 2009 May;64(5):819-26; discussion 826-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
  • OBJECTIVE: The neovascularization of malignant brain tumors is a poorly understood phenomenon.
  • These cells were measured in patients undergoing surgery for glioblastoma multiforme (GBM).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / blood. Glioblastoma / blood. Neovascularization, Pathologic / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biological Assay / methods. Endothelial Cells / metabolism. Endothelial Cells / pathology. Enzyme-Linked Immunosorbent Assay / methods. Female. Flow Cytometry. Follow-Up Studies. Glycoproteins / metabolism. Humans. Male. Middle Aged. Peptides / metabolism. Stem Cells / metabolism. Stem Cells / pathology. Umbilical Veins / pathology. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biomark Med. 2010 Feb;4(1):127-8 [20387308.001]
  • (PMID = 19404145.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


81. Jaeckle KA, Ballman K, Furth A, Buckner JC: Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology; 2009 Oct 13;73(15):1207-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma.
  • BACKGROUND: Clinical trials involving patients with glioblastoma (GBM) distinguish cohorts who are treated with enzyme-inducing anticonvulsants (EIAC).
  • CONCLUSIONS: Paradoxically, enzyme-inducing anticonvulsant (EIAC) use correlated with superior outcome of patients with glioblastoma.
  • [MeSH-major] Anticonvulsants / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / blood. Antineoplastic Agents / therapeutic use. Cross-Sectional Studies. Disease-Free Survival. Enzyme Induction. Female. Humans. Male. Middle Aged. Seizures / complications. Seizures / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 May;37(3):191-8 [9524077.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3871-9 [16921039.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):301-19 [11030437.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):285-90 [11071183.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] No To Shinkei. 1983 Jul;35(7):677-82 [6578801.001]
  • [Cites] N Engl J Med. 1984 Aug 16;311(7):442-8 [6749191.001]
  • [Cites] J Neurooncol. 1987;5(4):339-50 [3440876.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):83-90 [16639492.001]
  • [Cites] Stat Med. 1998 Oct 15;17(19):2265-81 [9802183.001]
  • [Cites] J Neurooncol. 2005 May;72(3):255-60 [15937649.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 [16467100.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Rev Neurol. 2006 Jun 1-15;42(11):681-90 [16736404.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3651-6 [16877733.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [CommentIn] Neurology. 2010 Apr 20;74(16):1330-1; author reply 1331 [20404316.001]
  • [CommentIn] Neurology. 2010 Apr 20;74(16):1329; author reply 1329-30 [20404315.001]
  • (PMID = 19822870.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 15083; United States / NCI NIH HHS / CA / P50 CA 108961; United States / NCI NIH HHS / CA / AND U10 CA 076001; United States / NCI NIH HHS / CA / U24 CA114740; United States / NCI NIH HHS / CA / U10 CA25224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2764724
  •  go-up   go-down


82. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer; 2010;10:30
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
  • BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months.
  • Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare.
  • METHODS: We performed a retrospective analysis of 35 patients with recurrent or progressive glioblastoma treated with 80 mg/m2 BCNU on days 1 on 3 intravenously at our department for efficacy, toxicity and prognostic factors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / pharmacology. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1998 Feb;168(2):114-20 [9499745.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9 [15990019.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):210-7 [16175848.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2168-73 [16220556.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):29-37 [16378904.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E5 [16709036.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):57-62 [19212704.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):161-71 [11508816.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Mutat Res. 1985 Jan-Mar;145(1-2):1-16 [3883145.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):654-8 [3021931.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):607-14 [2827051.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):573-7 [2926498.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):583-91 [1429079.001]
  • [Cites] Clin Neuropathol. 1999 Jan-Feb;18(1):1-8 [9988132.001]
  • (PMID = 20122270.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2837009
  •  go-up   go-down


83. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res; 2005 Jul 15;65(14):6029-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
  • Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.
  • Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.
  • Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death.
  • [MeSH-major] Apoptosis / genetics. Brain Neoplasms / pathology. MicroRNAs / physiology
  • [MeSH-minor] Cell Line, Tumor. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Oligonucleotides / administration & dosage. Oligonucleotides / genetics. Transfection

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024602.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS46569
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Oligonucleotides
  •  go-up   go-down


84. Kozak KR, Moody JS: Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol; 2009 Dec;11(6):833-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.
  • Giant cell glioblastoma (GC) is an uncommon subtype of glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. SEER Program. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2001 Jan;8(1):56-9 [11148082.001]
  • [Cites] J Neurosurg. 2008 Apr;108(4):642-8 [18377240.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1187-91 [12946225.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):219-26 [15309911.001]
  • [Cites] J Neurosurg. 1967 Jan;26(1):72-7 [6018784.001]
  • [Cites] Cancer. 1972 Oct;30(4):989-96 [4342859.001]
  • [Cites] Acta Neurochir (Wien). 1980;54(1-2):25-31 [7435292.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1179-86 [6260329.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):524-31 [2912529.001]
  • [Cites] Acta Neurol Scand. 1989 Mar;79(3):194-9 [2718738.001]
  • [Cites] Acta Neurochir (Wien). 1989;97(1-2):17-25 [2718792.001]
  • [Cites] Neurosurgery. 1991 Sep;29(3):385-8; discussion 388-9 [1833663.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Childs Nerv Syst. 1993 Feb;9(1):7-9 [8481945.001]
  • [Cites] Clin Neuropathol. 1995 Mar-Apr;14(2):118-23 [7606897.001]
  • [Cites] Pathol Int. 1995 Apr;45(4):275-82 [7550996.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):853-7 [9284834.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Nov;56(11):1236-41 [9370234.001]
  • [Cites] Childs Nerv Syst. 1998 Jun;14(6):288-91 [9694343.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):123-9 [10068201.001]
  • [Cites] Clin Neuropathol. 2004 Nov-Dec;23(6):286-91 [15584213.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):285-9 [15999285.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):314-9 [16133270.001]
  • [Cites] Cancer Genet Cytogenet. 2007 May;175(1):26-34 [17498554.001]
  • [Cites] J Neurosurg. 2001 Apr;94(4):605-11 [11302659.001]
  • (PMID = 19332771.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2802403
  •  go-up   go-down


85. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D: Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol; 2007 Jul;9(3):271-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
  • Glioblastoma multiforme (GBM) can present as either de novo or secondary tumors arising from previously diagnosed low-grade gliomas.
  • Results we present here show that grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas commonly display methylation of the PTEN promoter, a finding that is absent in nontumor brain specimens and rare in de novo GBMs.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6546-52 [16818626.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):621-7 [15196854.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50 [9560261.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2447-54 [9796977.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3005-10 [9865913.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1100-6 [12006525.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1178-84 [12006535.001]
  • [Cites] Cancer Cell. 2002 May;1(4):299-305 [12086841.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):74-80 [12203792.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Drugs R D. 2003;4(3):179-84 [12757405.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2000-6 [15026336.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207(2):215-20 [15072831.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Front Biosci. 2000 Jan 1;5:D213-31 [10702383.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):2057-64 [11062168.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):89-94 [11083071.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):22-6 [11149415.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):32-8 [11190805.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):493-7 [11179477.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):900-2 [11221878.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8571-80 [15467756.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):357-63 [15891996.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):768-76 [16084946.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Thyroid. 2006 Jan;16(1):17-23 [16487009.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):29-41 [11237521.001]
  • (PMID = 17504928.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97257; United States / NCI NIH HHS / CA / R01 CA52689; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA082783-06; United States / NCI NIH HHS / CA / R01 CA082783; United States / NCI NIH HHS / CA / CA082783-06; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1907411
  •  go-up   go-down


86. Kim B, Myung JK, Seo JH, Park CK, Paek SH, Kim DG, Jung HW, Park SH: The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma. J Neurol Sci; 2010 Jul 15;294(1-2):112-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma.
  • Glioblastoma (GBM) is a malignant CNS neoplasm.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism
  • [MeSH-minor] Adult. Age Factors. Brain / metabolism. Brain / surgery. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infratentorial Neoplasms / diagnosis. Infratentorial Neoplasms / metabolism. Infratentorial Neoplasms / mortality. Infratentorial Neoplasms / pathology. Male. PTEN Phosphohydrolase / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Prognosis. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / metabolism. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / pathology. Survival Analysis. Tumor Suppressor Protein p53 / metabolism


87. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature; 2008 Oct 23;455(7216):1061-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
  • Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas--the most common type of adult brain cancer--and nucleotide sequence aberrations in 91 of the 206 glioblastomas.
  • This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Breast Cancer Res Treat. 2008 Nov;112(2):217-27 [18074223.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):675-7 [16627990.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):709-14 [17050665.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1475-9 [16432179.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7426-9 [11606375.001]
  • [Cites] Brain Pathol. 2003 Jan;13(1):52-61 [12580545.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):591-8 [12650433.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Cancer Biol Ther. 2003 May-Jun;2(3):242-7 [12878856.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] DNA Repair (Amst). 2004 Nov 2;3(11):1389-407 [15380096.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4207-11 [1693434.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2495-9 [8669813.001]
  • [Cites] Hum Genet. 1997 Jan;99(1):88-92 [9003501.001]
  • [Cites] N Engl J Med. 1997 Jun 12;336(24):1713-20 [9180088.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):921-9 [16341083.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1079-99 [17485253.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e485 [17177598.001]
  • [Cites] Science. 2007 Sep 14;317(5844):1500 [17872428.001]
  • [Cites] Science. 2007 Oct 12;318(5848):287-90 [17872411.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Science. 2007 Dec 14;318(5857):1744-8 [18079394.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5213-8 [18362333.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):355-64 [18394558.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3286-94 [18451155.001]
  • [Cites] Anticancer Agents Med Chem. 2008 May;8(4):368-80 [18473722.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):258-63 [18464258.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] PLoS One. 2008;3(9):e3179 [18784837.001]
  • [ErratumIn] Nature. 2013 Feb 28;494(7438):506
  • (PMID = 18772890.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA126544-01; United States / NCI NIH HHS / CA / R01 CA099041-05; United States / NCI NIH HHS / CA / U24CA126561; United States / NCI NIH HHS / CA / CA126551-01; United States / NHGRI NIH HHS / HG / U54 HG003067; United States / NHGRI NIH HHS / HG / U54HG003273; United States / NCI NIH HHS / CA / U24CA126551; United States / NCI NIH HHS / CA / U24CA126543; United States / NCI NIH HHS / CA / U24 CA126561-01; United States / NCI NIH HHS / CA / U24CA126554; United States / NCI NIH HHS / CA / R01 CA099041; United States / NCI NIH HHS / CA / CA126554-01; United States / NCI NIH HHS / CA / U24 CA126546-01; United States / NHGRI NIH HHS / HG / HG003273-01; United States / NCI NIH HHS / CA / U24CA126544; United States / NHGRI NIH HHS / HG / HG003079-05; United States / NCI NIH HHS / CA / U24 CA126551; United States / NCI NIH HHS / CA / CA126544-01; United States / NHGRI NIH HHS / HG / U54HG003067; United States / NHGRI NIH HHS / HG / U54 HG003067-01; None / None / / R01 CA099041-05; United States / NIGMS NIH HHS / GM / T32 GM007753; United States / NCI NIH HHS / CA / U24 CA126543-01; United States / NHGRI NIH HHS / HG / U54 HG003273; United States / NCI NIH HHS / CA / CA126563-01; United States / NCI NIH HHS / CA / U24 CA126563-01; United States / NHGRI NIH HHS / HG / U54HG003079; United States / NCI NIH HHS / CA / U24 CA126554; United States / NHGRI NIH HHS / HG / U54 HG003273-01; United States / NCI NIH HHS / CA / U24 CA126561; United States / NCI NIH HHS / CA / U24 CA126551-01; United States / NCI NIH HHS / CA / U24 CA126543; United States / NCI NIH HHS / CA / U24CA126563; United States / NCI NIH HHS / CA / U24CA126546; United States / NHGRI NIH HHS / HG / U54 HG003079; United States / NCI NIH HHS / CA / CA126546-01; United States / NCI NIH HHS / CA / CA126561-01; United States / NHGRI NIH HHS / HG / U54 HG003079-05; United States / NCI NIH HHS / CA / U24 CA126554-01; United States / NCI NIH HHS / CA / CA126543-01; United States / NCI NIH HHS / CA / U24 CA126546; United States / NCI NIH HHS / CA / U24 CA126563; United States / NCI NIH HHS / CA / U24 CA126544; United States / NHGRI NIH HHS / HG / HG003067-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS68048; NLM/ PMC2671642
  • [Investigator] McLendon R; Friedman A; Bigner D; Van Meir EG; Brat DJ; Mastrogianakis GM; Olson JJ; Mikkelsen T; Lehman N; Aldape K; Yung WK; Bogler O; Weinstein JN; VandenBerg S; Berger M; Prados M; Muzny D; Morgan M; Scherer S; Sabo A; Nazareth L; Lewis L; Hall O; Zhu Y; Ren Y; Alvi O; Yao J; Hawes A; Jhangiani S; Fowler G; San Lucas A; Kovar C; Cree A; Dinh H; Santibanez J; Joshi V; Gonzalez-Garay ML; Miller CA; Milosavljevic A; Donehower L; Wheeler DA; Gibbs RA; Cibulskis K; Sougnez C; Fennell T; Mahan S; Wilkinson J; Ziaugra L; Onofrio R; Bloom T; Nicol R; Ardlie K; Baldwin J; Gabriel S; Lander ES; Ding L; Fulton RS; McLellan MD; Wallis J; Larson DE; Shi X; Abbott R; Fulton L; Chen K; Koboldt DC; Wendl MC; Meyer R; Tang Y; Lin L; Osborne JR; Dunford-Shore BH; Miner TL; Delehaunty K; Markovic C; Swift G; Courtney W; Pohl C; Abbott S; Hawkins A; Leong S; Haipek C; Schmidt H; Wiechert M; Vickery T; Scott S; Dooling DJ; Chinwalla A; Weinstock GM; Mardis ER; Wilson RK; Getz G; Winckler W; Verhaak RG; Lawrence MS; O'Kelly M; Robinson J; Alexe G; Beroukhim R; Carter S; Chiang D; Gould J; Gupta S; Korn J; Mermel C; Mesirov J; Monti S; Nguyen H; Parkin M; Reich M; Stransky N; Weir BA; Garraway L; Golub T; Meyerson M; Chin L; Protopopov A; Zhang J; Perna I; Aronson S; Sathiamoorthy N; Ren G; Yao J; Wiedemeyer WR; Kim H; Kong SW; Xiao Y; Kohane IS; Seidman J; Park PJ; Kucherlapati R; Laird PW; Cope L; Herman JG; Weisenberger DJ; Pan F; Van den Berg D; Van Neste L; Yi JM; Schuebel KE; Baylin SB; Absher DM; Li JZ; Southwick A; Brady S; Aggarwal A; Chung T; Sherlock G; Brooks JD; Myers RM; Spellman PT; Purdom E; Jakkula LR; Lapuk AV; Marr H; Dorton S; Choi YG; Han J; Ray A; Wang V; Durinck S; Robinson M; Wang NJ; Vranizan K; Peng V; Van Name E; Fontenay GV; Ngai J; Conboy JG; Parvin B; Feiler HS; Speed TP; Gray JW; Brennan C; Socci ND; Olshen A; Taylor BS; Lash A; Schultz N; Reva B; Antipin Y; Stukalov A; Gross B; Cerami E; Wang WQ; Qin LX; Seshan VE; Villafania L; Cavatore M; Borsu L; Viale A; Gerald W; Sander C; Ladanyi M; Perou CM; Hayes DN; Topal MD; Hoadley KA; Qi Y; Balu S; Shi Y; Wu J; Penny R; Bittner M; Shelton T; Lenkiewicz E; Morris S; Beasley D; Sanders S; Kahn A; Sfeir R; Chen J; Nassau D; Feng L; Hickey E; Barker A; Gerhard DS; Vockley J; Compton C; Vaught J; Fielding P; Ferguson ML; Schaefer C; Zhang J; Madhavan S; Buetow KH; Collins F; Good P; Guyer M; Ozenberger B; Peterson J; Thomson E
  •  go-up   go-down


88. Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M: Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res; 2005 Jul 15;65(14):6459-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms associated with asthma are inversely related to glioblastoma multiforme.
  • A reduced risk of primary malignant adult brain tumors is observed among people reporting asthma, hay fever, and other allergic conditions; however, findings may be attributed to prediagnostic effects of tumors or recall bias.
  • To determine whether asthma and allergic condition polymorphisms are inversely related to glioblastoma multiforme (GBM) risk, we conducted a population-based case-control study of 111 GBM patients and 422 controls.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Mar 1;9(4):549-59 [10699178.001]
  • [Cites] Hum Mutat. 2004 Jul;24(1):1-8 [15221783.001]
  • [Cites] Nature. 1999 Nov 25;402(6760 Suppl):B2-4 [10586888.001]
  • [Cites] Cancer Immunol Immunother. 2000 Aug;49(6):319-24 [10946814.001]
  • [Cites] Genome Res. 2001 Jan;11(1):152-62 [11156624.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Sep;25(3):377-84 [11588017.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):230-6 [11709756.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1103-9 [11861389.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Annu Rev Immunol. 2003;21:425-56 [12615888.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:232-42 [12724228.001]
  • [Cites] Genome Res. 2003 May;13(5):916-24 [12727908.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):423-8 [12845684.001]
  • [Cites] Biotechniques. 2003 Aug;35(2):292-6, 298 [12951770.001]
  • [Cites] J Allergy Clin Immunol. 2003 Oct;112(4):717-22 [14564349.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Oct;132(2):168-76 [14600429.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):79-85 [14610620.001]
  • [Cites] Clin Exp Allergy. 2004 Jan;34(1):26-31 [14720258.001]
  • [Cites] Respir Res. 2003;4:14 [14748924.001]
  • [Cites] Med Hypotheses. 2004;62(2):309-17 [14962646.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Glia. 2004 Apr 15;46(2):142-52 [15042582.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1515-25 [15173875.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1131-9 [15191930.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e261-9 [12456313.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):263-9 [15379594.001]
  • [Cites] Int J Epidemiol. 2004 Oct;33(5):945-6 [15319401.001]
  • [Cites] Cancer. 1992 May 15;69(10):2541-7 [1568177.001]
  • [Cites] Chest. 1993 Aug;104(2):600-8 [7802735.001]
  • [Cites] J Neuroimmunol. 1995 Jul;60(1-2):75-81 [7642750.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22428-33 [8798406.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):61-9 [8865004.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):664-72 [9259408.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1039-46 [9743522.001]
  • [Cites] Science. 1998 Dec 18;282(5397):2258-61 [9856949.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):87-8 [9920276.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):438-45 [10070943.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):155-60 [10389745.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1043-8 [15306533.001]
  • [Cites] Immunol Rev. 2004 Dec;202:191-202 [15546394.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8468-73 [15548720.001]
  • [Cites] Prog Neurol Surg. 2006;19:54-79 [17033147.001]
  • [Cites] Allergy. 2002 Feb;57(2):107-14 [11929412.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):252-9 [11979441.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1322-4, 1326, 1329 [12074163.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):426-30 [12110844.001]
  • [Cites] Genome Res. 2002 Sep;12(9):1401-7 [12213777.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 [12377741.001]
  • [CommentIn] Cancer Res. 2006 Mar 1;66(5):2878; author reply 2878-9 [16510612.001]
  • (PMID = 16024651.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA103379; United States / NCI NIH HHS / CA / R01CA103379
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / IL4R protein, human; 0 / Interleukin-13; 0 / Interleukin-4 Receptor alpha Subunit; 0 / Membrane Proteins; 0 / Receptors, Cell Surface; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; 0 / Trans-Activators; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM33 protein, human; EC 3.4.24.- / Metalloendopeptidases
  • [Other-IDs] NLM/ NIHMS2295; NLM/ PMC1762912
  •  go-up   go-down


89. Wang J, Miletic H, Sakariassen PØ, Huszthy PC, Jacobsen H, Brekkå N, Li X, Zhao P, Mørk S, Chekenya M, Bjerkvig R, Enger PØ: A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer; 2009;9:465
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reproducible brain tumour model established from human glioblastoma biopsies.
  • BACKGROUND: Establishing clinically relevant animal models of glioblastoma multiforme (GBM) remains a challenge, and many commonly used cell line-based models do not recapitulate the invasive growth patterns of patient GBMs.
  • The model provides combinations of angiogenic and invasive phenotypes and represents a good alternative to in vitro propagated cell lines for dissecting mechanisms of brain tumour progression.
  • [MeSH-major] Brain Neoplasms / pathology. Disease Models, Animal. Glioblastoma / pathology. Rats, Nude
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Transplantation / pathology. Rats. Reproducibility of Results. Transplantation, Heterologous. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16466-71 [17056721.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):761-8 [17955491.001]
  • [Cites] Oncogene. 2008 Sep 4;27(39):5182-94 [18469852.001]
  • [Cites] Neurosurgery. 2009 Jun;64(6):1139-46; discussion 1146-7 [19487894.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):29-34 [11135548.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6830-7 [11559558.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3085-92 [11753988.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):839-45 [11857365.001]
  • [Cites] Acta Neuropathol. 2003 Jan;105(1):49-57 [12471461.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):225-31 [12892228.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33 [14508090.001]
  • [Cites] Acta Pathol Microbiol Scand. 1968;74(4):465-86 [4313504.001]
  • [Cites] Cancer Res. 1975 Sep;35(9):2594-9 [167965.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1975 Nov;83(6):709-16 [1189920.001]
  • [Cites] Nature. 1978 Jul 27;274(5669):365-6 [307688.001]
  • [Cites] Prog Exp Tumor Res. 1984;28:18-31 [6484200.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):463-75 [2406382.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345-9 [1924398.001]
  • [Cites] Int J Cancer. 1991 Dec 2;49(6):938-9 [1959996.001]
  • [Cites] J Exp Anim Sci. 1992 Mar;35(1):33-48 [1606201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5645-9 [1608975.001]
  • [Cites] Anticancer Res. 1992 Sep-Oct;12(5):1399-401 [1444197.001]
  • [Cites] Anticancer Res. 1992 Sep-Oct;12(5):1403-6 [1332576.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1204-8 [8439965.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):283-6 [8517640.001]
  • [Cites] Anticancer Res. 1993 Jul-Aug;13(4):901-4 [8352558.001]
  • [Cites] J Neurooncol. 1994;22(3):191-200 [7760095.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):125-32 [10413165.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7929-37 [16278418.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Neuroimage. 2006 Feb 1;29(3):965-76 [16253523.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71 [16609043.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7429-37 [16885338.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9895-902 [17047051.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • (PMID = 20040089.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2810304
  •  go-up   go-down


90. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, Paglierani M, Pollo B, Taddei GL, Gallina P, Di Lorenzo N, Franceschetti S, Wanke E, Arcangeli A: hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer; 2005 Oct 3;93(7):781-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines.
  • In our study, hERG1 was found to be specifically overexpressed in high-grade astrocytomas, that is, glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Potassium Channels, Voltage-Gated / metabolism. Vascular Endothelial Growth Factor A / secretion
  • [MeSH-minor] Adult. Aged. Base Sequence. Cell Line, Tumor. Child. DNA Primers. Ether-A-Go-Go Potassium Channels. Female. Humans. Immunohistochemistry. Male. Middle Aged. Patch-Clamp Techniques. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 7;286(5):857-62 [11527377.001]
  • [Cites] Mol Biol Cell. 2005 Jun;16(6):2972-83 [15800067.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Xenobiotica. 2001 Aug-Sep;31(8-9):633-50 [11569530.001]
  • [Cites] Pflugers Arch. 2002 May;444(1-2):186-92 [11976931.001]
  • [Cites] Eur J Neurosci. 2002 Aug;16(3):415-28 [12193184.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1791-8 [12200695.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] Pathol Res Pract. 2002;198(9):627-33; discussion 635-8 [12440786.001]
  • [Cites] Br J Pharmacol. 2003 Jan;138(1):161-71 [12522086.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2947-55 [12431979.001]
  • [Cites] FASEB J. 2003 Feb;17(2):330-2 [12490549.001]
  • [Cites] Pflugers Arch. 2003 Feb;445(5):589-600 [12634931.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] J Neurosci. 2003 Jul 2;23(13):5572-82 [12843258.001]
  • [Cites] Drug News Perspect. 2003 Jun;16(5):291-8 [12942160.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Gene Expr Patterns. 2003 Dec;3(6):767-76 [14643686.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):972-5 [14645363.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):606-11 [14744775.001]
  • [Cites] Glia. 2004 Apr 1;46(1):63-73 [14999814.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Mol Pharmacol. 2004 May;65(5):1120-9 [15102940.001]
  • [Cites] Cancer Cell. 2004 May;5(5):405-6 [15144945.001]
  • [Cites] Neurosci Lett. 2004 Sep 30;368(3):249-53 [15364405.001]
  • [Cites] J Exp Ther Oncol. 2004 Jul;4(2):161-6 [15500011.001]
  • [Cites] Crit Rev Neurobiol. 1991;6(2):119-47 [1934088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3438-42 [8159766.001]
  • [Cites] J Physiol. 1995 Dec 1;489 ( Pt 2):455-71 [8847640.001]
  • [Cites] J Physiol. 1996 Oct 1;496 ( Pt 1):13-23 [8910192.001]
  • [Cites] J Neurophysiol. 1998 May;79(5):2782-93 [9582244.001]
  • [Cites] J Neurobiol. 1999 Mar;38(4):466-74 [10084682.001]
  • [Cites] FASEB J. 2000 Dec;14(15):2601-10 [11099479.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1722-9 [11104572.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6868-74 [11156382.001]
  • [Cites] J Neurophysiol. 2001 Feb;85(2):790-803 [11160513.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4923-31 [11080495.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neurosci. 2001 Jul 1;21(13):4609-24 [11425889.001]
  • [Cites] Eur J Neurosci. 1999 Mar;11(3):753-60 [10103069.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 1):C1405-10 [10362604.001]
  • [Cites] J Neurosci. 1999 Jul 15;19(14):5942-54 [10407033.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):445-9 [10448297.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):25018-25 [10455180.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • (PMID = 16175187.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / ERG1 potassium channel; 0 / Ether-A-Go-Go Potassium Channels; 0 / Potassium Channels, Voltage-Gated; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2361632
  •  go-up   go-down


91. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ: Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther; 2008 Apr;8(4):541-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
  • BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):777-85 [11901186.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Acta Radiol. 2002 Jul;43(4):354-9 [12225474.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20 [12234397.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):904-11 [16741298.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Cancer Res. 1991 Oct 15;51(20):5760-5 [1717153.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1593-607 [17134364.001]
  • [Cites] Hum Gene Ther. 2003 Jun 10;14(9):883-95 [12828859.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S35-40 [17145523.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 [17236958.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):141-50 [17115285.001]
  • [Cites] Neuroscience. 2007 Mar 30;145(3):795-811 [17320297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37 [17234361.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3449-59 [17575207.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7055-8 [17671170.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S116-9 [17512217.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):412-23 [17622648.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):733-6 [17882276.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5670-4 [17908955.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):635-41 [10682677.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1322-9 [11355942.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 [11504114.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6020-4 [11507045.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7501-6 [11606386.001]
  • [Cites] Science. 2002 Feb 1;295(5556):858-61 [11823643.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):236-41 [12517803.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5822-7 [7694795.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1317-26 [8167412.001]
  • [Cites] Lancet. 1994 Jul 9;344(8915):82-6 [7516992.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):520-9 [7525492.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7788-95 [8631822.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):3131-9 [9399960.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10820-5 [9724788.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):363-70 [15739567.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):558-65 [15705616.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4162-71 [15867205.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6270-9 [16144931.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8218-23 [16166297.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):452-64 [16212810.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8145-57 [16299247.001]
  • [Cites] Oncology. 2005;69 Suppl 3:11-6 [16301831.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):318-26 [16389944.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):409-17 [16484420.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1449-53 [16549839.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Clin Neurosurg. 2005;52:384-8 [16626098.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5018-22 [16951216.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Radiology. 2003 Aug;228(2):523-32 [12819338.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:169-77 [14531575.001]
  • [Cites] Mol Cancer Res. 2004 Jan;2(1):36-42 [14757844.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86 [15207817.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5 [15479484.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [CommentIn] Expert Opin Biol Ther. 2008 Oct;8(10):1449-53 [18774913.001]
  • (PMID = 18352856.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108786-029003; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NCI NIH HHS / CA / CA108786-059003; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / NS020023-268626; United States / NINDS NIH HHS / NS / NS020023-240020; United States / NINDS NIH HHS / NS / NS020023-220020; United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / P50 CA108786-039003; United States / NINDS NIH HHS / NS / NS020023-250020; United States / NINDS NIH HHS / NS / P50 NS020023-210020; United States / NCI NIH HHS / CA / CA108786-049003; United States / NCI NIH HHS / CA / P50 CA108786-059003; United States / NCI NIH HHS / CA / P50 CA108786-029003; United States / NINDS NIH HHS / NS / P50 NS020023-230020; United States / NCI NIH HHS / CA / CA108786-05S19003; United States / NCI NIH HHS / CA / P50 CA108786-049003; United States / NCI NIH HHS / CA / CA11898; United States / NCI NIH HHS / CA / CA108786-039003; United States / NINDS NIH HHS / NS / P50 NS020023-240020; United States / NINDS NIH HHS / NS / P50 NS020023-268626; United States / NCI NIH HHS / CA / P50 CA108786-019003; United States / NINDS NIH HHS / NS / P50 NS020023-220020; United States / NCI NIH HHS / CA / P50 CA108786-05S19003; United States / NCI NIH HHS / CA / CA108786-019003; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / P50 NS020023-250020; United States / NCI NIH HHS / CA / R37 CA011898; United States / NINDS NIH HHS / NS / NS020023-210020; United States / NINDS NIH HHS / NS / NS020023-230020
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 139
  • [Other-IDs] NLM/ NIHMS180495; NLM/ PMC2871667
  •  go-up   go-down


92. Chaichana K, Parker S, Olivi A, Quiñones-Hinojosa A: A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg; 2010 May;112(5):997-1004
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme.
  • OBJECT: Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults.
  • METHODS: Cases involving adult patients who underwent surgery for an intracranial primary (de novo) GBM between 1997 and 2007 at The Johns Hopkins Hospital, an academic tertiary-care institution, were retrospectively reviewed.
  • [MeSH-major] Brain Neoplasms. Glioblastoma. Program Development
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Preoperative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817542.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Piccirilli M, Salvati M, Bistazzoni S, Frati A, Brogna C, Giangaspero F, Frati R, Santoro A: Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Tumori; 2005 May-Jun;91(3):256-60
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks.
  • The association between breast cancer and glioblastoma multiforme has not been amply analyzed in the literature.
  • We describe 11 female patients with a diagnosis of glioblastoma multiforme who were treated when younger for breast cancer.
  • Another important point of view is represented by the chemotherapy treatment of breast cancer, which could have a carcinogenic effect and explain the growth of glioblastoma.
  • This consideration, in our opinion, is important, because more effort should be made to understand the pathogenesis of glioblastoma multiforme and to improve the therapeutic approaches.
  • [MeSH-major] Brain Neoplasms / etiology. Breast Neoplasms / complications. Glioblastoma / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasms, Second Primary. Time Factors


94. Schley M, Ständer S, Kerner J, Vajkoczy P, Schüpfer G, Dusch M, Schmelz M, Konrad C: Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull; 2009 Jun 30;79(5):333-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.
  • BACKGROUND AND OBJECTIVES: The most abundant malignant brain tumor in human is glioblastoma and patients with this type of tumor have a poor prognosis with high mortality.
  • Glioblastoma are characterized particularly by fast growth and a dependence on blood vessel formation for survival.
  • The distribution of CB1 and CB2 receptors in glioblastoma and associated endothelial vessels is still unknown.
  • METHODS: Tissue samples were collected consecutively after neurosurgery of 19 patients suspected glioblastoma and examined immunohistochemically for CB1 and CB2 receptor expression.
  • In glioblastoma endothelial cells, CB1 and CB2 receptors were present in about 38% and 54% of the cells respectively.
  • In comparison to CB1, an elevated CB2 receptor expression was identified in glioblastoma.
  • CONCLUSIONS: The abundant expression and distribution of CB2 receptors in glioblastoma and particularly endothelial cells of glioblastoma indicate that impaired tumor growth in presence of CB may be associated with CB2 activation.
  • Selective CB2 agonists might become important targets attenuating vascular endothelial growth factor (VEGF) signalling and thereby diminishing neoangiogenesis and glioblastoma growth.
  • [MeSH-major] Brain Neoplasms / metabolism. Endothelial Cells / metabolism. Glioblastoma / metabolism. Receptor, Cannabinoid, CB1 / metabolism. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antigens, CD31 / metabolism. Brain / blood supply. Brain / metabolism. Endothelium, Vascular / metabolism. Female. Humans. Immunohistochemistry. Male. Microscopy, Fluorescence. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480992.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Receptor, Cannabinoid, CB1; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


95. Carter AN, Cole CL, Playle AG, Ramsay EJ, Shervington AA: GPR26: a marker for primary glioblastoma? Mol Cell Probes; 2008 Apr;22(2):133-7
Guide to Pharmacology. gene/protein/disease-specific - GPR26 - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GPR26: a marker for primary glioblastoma?
  • Glioblastomas are highly malignant brain tumours; they have been described as one of the most deadly human cancers.
  • Two conceptual classifications of the condition exist: primary (de novo), which does not exhibit prior disease and secondary glioblastoma, which develops from a pre-existing glioma.
  • This study investigates whether GPR26 is differentially transcribed in glioblastoma tissue from patients of different ages, in order to define a candidate genetic marker.
  • The transcriptional profile of GPR26 was compared in nine samples: seven glioblastoma tissues and two normal brain tissues using PCR.
  • Despite GPR26 being present in the glioblastoma tissues, it was not transcribed in any of the four cell lines tested.
  • This study has identified GPR26 to be a genetic indicator of primary glioblastoma, suggesting that it could be a suppressor of primary glioblastoma development.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Receptors, G-Protein-Coupled / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037267.001).
  • [ISSN] 0890-8508
  • [Journal-full-title] Molecular and cellular probes
  • [ISO-abbreviation] Mol. Cell. Probes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPR26 protein, human; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled
  •  go-up   go-down


96. Yamahara T, Numa Y, Oishi T, Kawaguchi T, Seno T, Asai A, Kawamoto K: Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathol; 2010 Oct;27(2):81-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging.
  • Even when we successfully perform a total extirpation of glioblastoma macroscopically, we often encounter tumor recurrence.
  • There has so far been no report regarding mapping of tumor cell infiltration and DNA histogram by flow cytometry, comparing the neuroimaging findings with the autopsy brain findings.
  • The autopsy brain was cut in 10-mm-thick slices, in parallel with the OM line.
  • In the autopsy brain, the tumor was easily identified macroscopically.
  • When performing surgery on glioblastoma, a macroscopic total extirpation of the tumor as defined by the contrast-enhanced area in MRI is therefore considered to be insufficient for successfully reducing tumor recurrence.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Autopsy. Brain / pathology. DNA, Neoplasm / metabolism. Female. Flow Cytometry. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Thalamic Diseases / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046309.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


97. Ulitin AIu, Zabrodskaia IuM, Oliushin VE, Sokolova TV, Petrov AA, Burnin KS, Gurchin AF: [Metastatic glioblastoma in a submandibular lymph node (a rare case)]. Vopr Onkol; 2009;55(2):230-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic glioblastoma in a submandibular lymph node (a rare case)].
  • Extraneural metastases from glioblastoma are rare.
  • A case of metastatic right parietal lobe glioblastoma in cervical node after repeat craniotomy is presented.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Lymph Nodes / pathology. Parietal Lobe
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Mandible

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514382.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


98. Culicchia F, Cui JG, Li YY, Lukiw WJ: Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme. Neuroreport; 2008 Jun 11;19(9):981-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme.
  • Glioma and glioblastoma multiforme constitute rapidly proliferating glial cell tumors whose pathogenic mechanisms are not well understood.
  • This study examined proinflammatory and neurodegenerative gene expression in five American Tissue Culture Collection glioma and glioblastoma multiforme tumor cell lines and in 14 glioma and glioblastoma samples obtained from human brain biopsy.
  • These studies suggest that glioma and glioblastoma exhibit robust upregulation of proinflammatory and neurodegenerative genetic markers that may contribute to the pathobiology, phenotype, and proliferation of glial cell growth.
  • [MeSH-major] Amyloid beta-Protein Precursor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Up-Regulation / physiology
  • [MeSH-minor] Adult. Antigens, Human Platelet / genetics. Antigens, Human Platelet / metabolism. Cell Line, Tumor. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Female. Humans. Interleukin-1beta / metabolism. Male. Middle Aged. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521005.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Antigens, Human Platelet; 0 / Interleukin-1beta; 0 / RNA, Messenger; 0 / human platelet antigen 1b; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


99. Atukeren P, Kemerdere R, Kacira T, Hanimoglu H, Ozlen F, Yavuz B, Tanriverdi T, Gumustas K, Canbaz B: Expressions of some vital molecules: glioblastoma multiforme versus normal tissues. Neurol Res; 2010 Jun;32(5):492-501
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expressions of some vital molecules: glioblastoma multiforme versus normal tissues.
  • OBJECTIVE: The aim of this study was to assess plasma and/or tissue levels of adhesion and apoptotic molecules, cytokines, nitric oxide metabolites, levels of lipid peroxidation, myeloperoxidase and superoxide dismutase in patients with glioblastoma multiforme and controls.
  • METHODS: All the molecules were evaluated in 25 tumors and 30 controls: 15 were normal healthy subjects for plasma and 15 were normal brain tissues that were collected during autopsy.
  • DISCUSSION: These results suggest that there is a complex relationship between pro- and anti-apoptotic molecules in glioblastoma multiforme pathogenesis.
  • Thus, targeting multiple pathways with advanced chemotherapeutic agents or radiotheraupetic regimens following total resections might be helpful in patients with glioblastoma multiforme since preventing a single pathway does not seem to be reasonable.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / blood. Brain Neoplasms / metabolism. Glioblastoma / blood. Glioblastoma / metabolism
  • [MeSH-minor] Adult. Aged. Blood Chemical Analysis. Case-Control Studies. Child. Female. Humans. Male. Middle Aged. Young Adult